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1 General introduction and aims of this thesis
Partly based on:
Potentials of interferon therapy in 
the treatment of pancreatic cancer
Stephanie Booy, Leo J. Hofland and Casper H.J. van Eijck.
J Interferon Cytokine Res., 2014 Dec 31. [Epub ahead of print].
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chapter 11.  Pancreatic cancer
Pancreatic cancer, with 165.100 estimated new cases and 161.800 estimated deaths, is the 
fourth leading cause of cancer related death in the western world1. Surgery is the only cura-
tive therapy, but due to early metastasis and/or locally advanced disease only 15-20% of the 
patients are eligible for resection at time of presentation. Nevertheless, even after successful 
surgery prognosis remains poor, resulting in a total overall 5-year survival rate of less than 6% 2.
In addition to tumors of pancreatic ductal origin, in the same anatomical area other 
tumors may arise as well. These cancers are known as periampullary cancers consisting of 
distal bile duct and ampullary carcinoma’s and present with the same clinical symptoms as 
pancreatic cancer. However, after correction for tumor size, positive lymph nodes and stage, 
the survival of periampullary cancer patients is significant favorable compared to pancreatic 
cancer patients (45 months versus 15 months, respectively), which may indicate that periam-
pullary cancers represent a different family of tumors with a different biological behavior. Nev-
ertheless, patients with periampullary cancers are subjected to the same surgical procedure 
as patients with pancreatic carcinomas3,4. Additionally, it has recently been demonstrated that 
periampullary cancer patients have a small survival benefit of adjuvant chemotherapy as well5.
Current chemotherapeutic agents used in pancreatic cancer, mainly, consist of gem-
citabine and 5-FU, which may be complemented with platinum analogues (cisplatin, 
oxaliplatin), capecitabine, taxanes and irinotecan. The use of adjuvant radiotherapy in the 
treatment of pancreatic cancer is still controversial and depends on the country in which 
the patient is being treated (chemo-radiotherapy in North America versus chemotherapy 
alone as standard in Europe)6. Pancreatic cancers are very heterogeneous tumors with a 
restricted vasculature and appear to be very resistant to chemo- and radiotherapy7. Re-
cently, the importance of the tumor-stroma component in pancreatic cancer is becoming 
clearer. The desmoplastic reaction of the stroma to the cancer is an active player in the 
carcinogenesis of pancreatic cancer and can explain the aggressive behavior of this tumor. 
In addition, it has been described that increased levels of stroma correlate with poorer 
prognosis, although in pre-clinical and clinical trials, targeting the stromal component has 
been associated with a better prognosis for patients with pancreatic cancer7,8. Neverthe-
less, despite the multiple different treatment strategies that have been attempted over the 
last 30 years, pancreatic cancer survival has barely improved. Nowadays median survival 
of patients with pancreatic cancer varies from 24.1 months for patients having stage IA 
disease, to 4.5 months for patients with metastatic, stage V disease9. Therefore, in order to 
improve survival of patients with pancreatic cancer new treatment strategies are warranted.
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A few years ago several clinical studies showed some evidence that there might be a 
role for interferon-α in the adjuvant treatment of pancreatic cancer10-14. Although the only 
randomized clinical trial did not show a significant increase in overall survival, the difference 
in median survival of 3.6 months implies that some patients probably benefited from the 
experimental treatment 14. Furthermore, median survival in these clinical trials was notably 
high and therefore this treatment strategy seems promising.
More recently, several in vitro studies showed promising results regarding IFN-β therapy 
and demonstrated that in human pancreatic cancer cells IFN-β induces, already at low 
concentrations, a much more potent anti-cancer effect compared to IFN-α. Additionally, 
IFN-β is capable to induce strong chemo- and radiosensitizing effects even in cell lines non-
responsive to IFN-α. However, the use of interferons (IFNs), mainly IFN-α, in the treatment of 
pancreatic cancer remains controversial15-17.
2.  interferons
Interferons are cytokines that have been discovered over 50 years ago, and are known to 
have antiproliferative, antiviral and immunoregulatory activities18-22. They can be divided 
into two major categories, type I and type II IFNs. Type I IFNs are produced in direct response 
to viral infection and include IFN-α,-β, -ω,-δ and –τ. Type II IFNs consists only of IFN-γ23. Of 
all the various subtypes, IFN-α and IFN-β are the most frequently used subtypes in clinical 
practice and subsequent information in this review refers to these subtypes. In humans, 
IFN-α is predominately synthesized by leukocytes. IFN-β is particularly synthesized by 
fibroblasts21,24. There are 13 human IFN-α genes located on the short arm of chromosome 9 
encoding for 12 different functional human IFN-α proteins since there are two genes (α1 and 
α13) that encode for identical proteins. The human IFN-β gene is present as a single copy 
on chromosome 9. IFN-α and –β share around 30% of their amino acid sequence identity25.
2.1  type i interferon receptor
Both IFN-α as IFN-β act via the type I IFN receptor complex (IFNAR), which is composed of two 
subunits; IFNAR-1 and IFNAR-2. Of the IFNAR-2 subunit there are three isoforms known that 
are differentially spliced from a common gene. IFNAR-2a is the soluble form and can act as 
a dominant negative regulator of free IFNs. IFNAR-2b is the shorter form, lacking regions of 
the cytoplasmic domain, is unable to couple to signal transduction but may act as a negative 
regulator of IFN responses. The latter isoform, the IFNAR-2c, contains the entire cytoplasmic 
domain and along with the IFNAR-1 makes up the functional IFN receptor complex21,26,27.
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chapter 1Binding of IFNs to the receptor complex leads to the activation and phosphorylation 
of the receptor associated Janus kinase JAK1 and tyrosine kinase TYK2 and thereby to the 
phosphorylation of signal transducer and activator of transcription (STAT) proteins. After 
phosphorylation, STAT-1 and STAT-2 forms a complex named IFN-stimulated gene factor-3 
(ISGF3) with the DNA binding protein p48. The ISGF3 complex moves into the nucleus 
where it binds to IFN-stimulated response elements (ISRE) resulting in transcription of 
interferon stimulated genes (ISGs) encoding for multiple different proteins that effectuate 
the different activities of IFNs19,20,23,28(Figure 1).
figure 1: Signaling pathway activated by IFN-α/-β via the type I IFN receptor complex (IFNAR-1 and IF-
NAR-2c). Binding of IFN-α/-β to the receptor complex leads to the phosphorylation of the receptor-associ-
ated tyrosine kinases which in their turn phosphorylate STAT-1 and STAT-2. Together with the DNA binding 
protein p48 the ISGF3 complex is formed which enter the nucleus and binds to interferon stimulated 
response element (ISRE) resulting in the transcription of interferon stimulated genes (ISGs).
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2.2  antitumor defense processes of type i ifns
In addition to the antiproliferative, antiviral and immunoregulatory activities IFN-α and-β, both 
cytokines are also involved in cell differentiation and antitumor defense processes (figure 2). 
There are several mechanisms for the anti-cancer effects of IFN-α and-β. The direct effects 
include the induction of apoptosis and blocking of the cell cycle. The initiation of apoptosis 
can act through an extrinsic pathway by the activation of the death receptors, via an intrinsic 
and/or mitochondrial pathway or by the stress kinase cascade29-32. IFNs can affect different 
phases of the mitotic cycle, mostly IFN therapy results in a cell cycle arrest at the G1 phase or 
in a prolongation and accumulation of cells in the S-phase due to the disability to complete 
DNA replication by the down regulation and impaired activity of cyclin and cyclin dependent 
kinases.30,33,34. As a result, tumor cells are more vulnerable to chemo- and radiotherapy.
figure 2: Overview of the activities of IFN-α and –β in humans. Besides the direct effects, several indirect 
anti-cancer effects of type I IFNs have been described. These effects include the induction of immuno-
modulatory functions, like the activation of cytotoxic t-lymphocytes, natural killer (NK)-cells and mono-
cytes35 and the induction of increased cell surface expression of class I major histocompatibility complex 
antigens36,37. Furthermore, several non-immunomodulatory host effects, like the inhibition of transcrip-
tion and secretion of anti-angiogenic factors38-40 and the interaction between tumor and surrounding 
stroma41 have been demonstrated.
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chapter 1Besides the direct effects, several indirect anti-cancer effects of type I IFNs have been 
described. These effects include the induction of immunomodulatory functions, like the 
activation of cytotoxic t-lymphocytes, natural killer (NK)-cells and monocytes35 and the 
induction of increased cell surface expression of class I major histocompatibility complex 
antigens36,37. Furthermore, several non-immunomodulatory host effects, like the inhibition 
of transcription and secretion of anti-angiogenic factors38-40 and the interaction between 
tumor and surrounding stroma41 have been demonstrated.
3. interferons in cancer treatment
The wide range of potential anti-cancer effects of IFNs led to exploration of IFN-α and -β, in 
the treatment of multiple malignant and viral diseases. Although IFN-α and –β act via the 
same receptor complex, they display significant functional differences and do not share the 
same clinical indications (Table 1).
3.1  interferon-α
In 1985 IFN-α was approved for the treatment of hairy cell leukemia42 hereafter it was found 
that IFN-α was therapeutically effective in the treatment of other malignancies like chronic 
myelogenous leukemia43, multiple myeloma44, malignant cutaneous melanoma45, Kaposi’s 
sarcoma46, gastroenteropancreatic neuroendocrine tumors47 and renal cell carcinoma48 as 
well. However, IFN-α therapy can give considerable side effects, which may be acute (fever, 
chills, headache and myalgia) or delayed (nausea, vomiting, fatigue, anorexia, leukopenia 
and less frequently hyper- or hypothyroidism, neutropenia and neurotoxicity) and are usu-
ally dependent on the amount of the dosage. Some other side effects that were reported are 
depression and confusion (0.1-1% of the patients) and rarely, though notable, (attempted) 
suicide (0.01-0.1% of the patients). Nowadays, due to the increased understanding of mo-
lecular mechanisms of various types of cancer, IFN-α is only commonly employed as a first 
line, salvage, therapy in the treatment of metastatic renal cell carcinoma and malignant 
melanoma.
3.2  interferon-β
To date, the use of IFN-β is only approved in the treatment of relapsing remitting multiple 
sclerosis(RRMS). Although multiple clinical studies have been conducted regarding the use 
of IFN-β in RRMS, the mechanism underlying the therapeutic effects is not fully understood. 
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Nevertheless, IFN-β therapy reduces relapse rates in approximately one third of the patients 
and reduces the appearance of new MRI lesions in around two third of the patients49-51.
In cancer treatment, simultaneous administration of IFN-β with adjuvant treatment has 
been clinically tested in phase II and III trials in patients with glioblastoma52, metastatic 
breast cancer53,54, advanced pancreatic cancer55 and in patients with locally advanced non-
small-cell lung cancer56. In patients with locally advanced non-small-cell lung cancer the 
concomitant use of IFN-β did not lead to an improvement in the 1-year survival. In one of 
the two studies regarding the additional use of IFN-β in metastatic breast cancer and in the 
phase II trials in patients with glioblastoma and advanced pancreatic carcinoma a trend 
towards a prolonged progression free survival was observed52,53,55.
table 1. Clinical indications of type I interferons
Interferon-type Name Indications
Interferon-α2a Roferon-A Hairy cell leukemia
AIDS related Kaposi sarcoma
Chronic hepatitis B
Chronic hepatitis C
Cutaneous T-cell lymphoma
Chronic myeloid leukemia
Follicular non-hodgkin lymphoma
Advanced renal cell carcinoma
Malignant melanoma
Interferon-α2b Intron-A Hairy cell leukemia
Juvenile laryngeal pappilomatosis
AIDS related Kaposi sarcoma
Chronic hepatitis B
Chronic hepatitis C
Multiple myeloma
Chronic myeloid leukemia
Non-Hodgkin lymphoma
Carcinoid tumor
Malignant melanoma
Peg-Interferon-α2a Pegasys Chronic hepatitis B
Chronic hepatitis C
Peg-Interferon-α2b Pegintron Chronic hepatitis C
Interferon-β1a Avonex
Rebif
Relapsing remitting multiple sclerose
Interferon-β1b Betaferon
Betaseron
Relapsing remitting multiple sclerose
Adapted from: Bracarda et al.
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chapter 14.  interferons in the treatment of Pancreatic cancer - IN vItro
One of the first reported in vitro studies regarding the anti-cancer effect of type I IFNs in 
human pancreatic cancer cell lines was in 1991 by Matsubara et al57, in which the antipro-
liferative effects of natural human tumor necrosis factor-α (TNF-α), IFN-α and interferon-γ 
(IFN-γ) alone and in combination, in five human pancreatic cancer cell lines (HuP-T1, HuP-T3, 
HuP-T4, BxPC-3 and MIA-PaCa-2) were described. After 96 hours of incubation with IFN-α, 
the authors showed a dose-dependent growth inhibition, ranging from 35 to 70%, in four of 
the five cell lines57. In 1996, Rosewicz et al58 described that protein kinase C (PKC) expression 
might determine the sensitivity of pancreatic cancer cells to the antiproliferative effects of 
IFN-α, although this mechanism is not completely elucidated.58.
Despite the paucity of available in vitro data, multiple clinical studies were conducted 
in the following years, owing to the poor perspectives and limited treatment options of 
pancreatic cancer patients. Nearly 10 years later several researchers aimed to expand the 
knowledge on the anti-cancer effects of IFNs in the treatment of pancreatic cancer. In 2005, 
the group of Angela Marten from the university of Heidelberg determined whether IFN-α 
acts in a synergistic manner when combined with chemotherapy (5-FU and cisplatin) and/ 
or radiotherapy in 8 human pancreatic cancer cell lines. The results of this study showed 
that IFN-α has a limited chemosensitizing effect, but a direct inhibitory effects (cell survival, 
apoptosis and proliferation) and potent radiosensitizing effects. In addition, the authors 
showed that three cell lines secreted VEGF and that INF-α was able to inhibit this enhanced 
VEGF secretion of 5-FU and cisplatin resistant cells. Besides that, IFN-α was able to diminish 
the decrease of MHC class I expression occurring after 5-FU treatment59.
Subsequently, the same research group demonstrated that IFN-α is capable to activate 
NK-cells against pancreatic carcinoma cells and that treatment with 5-FU makes pancreatic 
cancer cells more susceptible against these immunological attacks60.
Other research groups focused more on the antiproliferative effects of IFNs and the 
importance of the IFN receptor expression. Saidi et al.61 showed that pancreatic cancer 
cell lines differently express the IFNAR-2 receptor and that cell lines with a higher IFNAR-2 
receptor expression are more prone to the direct effects (cell growth and apoptosis) of IFNs. 
Moreover, Vitale et al.30 evaluated the role of the type I IFN receptor in the responsiveness 
to IFN-α and –β as well. The growth inhibitory effects of IFN-α and –β were determined in 
three human pancreatic cancer cell lines as well as the mechanisms that are involved in this 
growth inhibition (apoptosis and cell cycle arrest). Furthermore, the presence of all type I 
IFN receptor subunit transcripts (e.g. IFNAR-1, IFNAR-2 total, IFNAR-2a, -2b and -2c) were 
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demonstrated. The study of Vitale et al. showed, for the first time, that the antitumor activity 
of IFN-β in human pancreatic cancer cell lines is significantly more effective compared to 
the effects of IFN-α. IFN-β induces a more potent and early apoptosis and cell cycle arrest 
compared to IFN-α. In addition, this effect was even more pronounced in cell lines with a 
higher receptor expression, suggesting an association between type I IFN receptor expres-
sion and the response to IFN-α and –β.
The promising effects of IFN-β on human pancreatic cancer cell lines encouraged other 
research groups to determine the chemo and radiosensitizing properties of IFN-β as well. 
The study of Jost et al.62 showed a heterogeneous response to IFN-α and  –β to ionizing 
radiation in 10 human pancreatic cancer cell lines. IFN-β induced stronger cytotoxic and 
radiation enhancing effects compared to IFN-α, which seems to be due to the increase of 
radiation induced apoptosis by IFN pre-treatment. The potent radiosensitizing properties of 
IFN-β were confirmed by the study of Morak et al63. Moreover, it is demonstrated that IFN-β 
is able to act synergistically with gemcitabine to reduce the cell growth of pancreatic cancer 
cells, even in cell lines that are non-responsive to IFN-α and have a low IFNAR-2 expres-
sion.64 However, the correlation between type I interferon receptor (IFNAR-1 and IFNAR-2) 
expression and response of pancreatic cancer cells to type I interferons (IFN-α and IFN-β) 
has not been demonstrated to date.
5.  interferons in the treatment of Pancreatic cancer – IN vIvo 
and ex vIvo
Following in vitro research, the next step is to demonstrate the effects of IFNs in vivo. Despite 
the fact that the potent anti-tumor effects of IFN-β were demonstrated in vitro, all the in vivo 
research that has been done is solely focused on the effects of IFN-α.
5.1 interferon-α therapy in vivo in experimental models
In the first in vivo study researchers aimed to determine the most optimal and effective 
IFN-α treatment schedule in a orthotopic pancreatic cancer mouse model. Mice were 
randomized in different treatment groups receiving divergent doses of IFN-α at different 
time points with or without gemcitabine. After 35 days of treatment with daily subcutane-
ous injections of 10.000 IU IFN-α and twice a week intraperitoneal injections of 125 mg/
kg gemcitabine pancreatic tumor growth and the number of metastasis was significantly 
inhibited in nude mice. Treatment alone with IFN-α was effective as well, though combina-
tion therapy further decreased tumor growth and significantly prolonged survival. Further-
017
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chapter 1more, tumors of treated mice showed a significant increase of apoptotic cells, a decrease 
in mean vessel density and a down regulation of bFGF, MMP-9, IL-8 and VEGF which, in 
turn, can be responsible for the reduced tumor growth65. Only two other studies used the 
cytotoxic, and most active, agent gemcitabine as combination therapy as well. The study 
of Saidi et al.66 mainly focused on the relationship between the IFN receptor status of the 
pancreatic cancer cell lines that were injected orthotopically in nude mice and the effect 
of IFN-α combined with gemcitabine. The authors showed that IFN-α treatment enhanced 
the effects of gemcitabine therapy. In addition, treatment with IFN-α appeared to be only 
effective in the IFNAR-2 expressing cell line66. The other study that explored the effects of 
IFN-α and gemcitabine demonstrated that IFN-α is able to increase the chemosensitivity for 
gemcitabine of pancreatic cancer cells with cancer stem cell properties in a subcutaneous 
xenograft mice model67.
Another study demonstrated the effect of IFN-α in addition to S-1, an oral fluoropy-
rimidine derivative. In a subcutaneous heterotopic xenograft model a significant effect of 
the combination therapy on the reduction of tumor growth was observed. Furthermore, 
an inhibition of angiogenic and survival factors (VEGF, bFGF, MMP-2, MMP-7, MMP-9) was 
demonstrated, as well as a downregulation of 6 genes that are linked to cell invasion, pro-
liferation and metastasis68.
Three studies, all from the group of Heidelberg, investigated the effects of IFN-α 
combined with mainly 5-FU and focused on the different anti-cancer features of IFN-α69-71. 
First, the effect of IFN-α combined with 5-FU on tumor growth and immune response was 
determined. The addition of IFN-α to 5-FU, and cisplatin treatment significantly improved 
the outcome. In contrast to the in vitro results, the effect of IFN-α combined with radio-
therapy were less clear due to adverse reactions in the mice. Furthermore, by the addition 
of IFN-α an improved adherence of leukocytes to the endothelium was observed which is 
of importance for the infiltration of immune cells into the tumor70.
In the second study the authors showed, by intravital microscopy, in an orthotopic mu-
rine pancreatic cancer model, that the addition of IFN-α to 5-FU has strong anti-angiogenic 
properties. Tumor regression, a decrease in serum VEGF and VEGF receptor expression and 
a reduced, and less chaotic in structure, vessel density was demonstrated. Furthermore, 
treatment with IFN-α monotherapy led to the normalization of vessel structure assuming 
that this results in a better distribution of chemotherapy69. Lastly, the effect of IFN-α on 
multidrug resistance was demonstrated in the same murine orthotopic pancreatic cancer 
model. After combined treatment with IFN-α and chemotherapy (5-FU, cisplatin and 
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gemcitabine) a decrease (though not in all treatment modalities significant) of multidrug 
resistance-associated proteins (MRPs) and P-glycoprotein was observed as well as a sig-
nificantly reduced tumor size, peritoneal carcinomatosis, hepatic seeding and pulmonary 
metastasis71.
In conclusion, the in vivo effect of adjuvant IFN-α therapy is at multiple levels, with 
different combination therapies broadly demonstrated. Nevertheless, the effects of IFN-β 
treatment in vivo remain unexposed.
5.2  ex vivo interferon receptor expression
Type I IFNs exert their effect via the type I IFN receptor. The importance of the receptor for 
the direct anti-cancer effect has been described for melanoma, breast cancer, fibrosarcoma 
and hepatocellular cancer cells. Surprisingly, in none of the pancreatic cancer patients 
receiving adjuvant IFN-α therapy IFN receptor status known.
Two, nearly identical, studies of Saidi et al.72,73 demonstrated the IFNAR-α/β (IFNAR-2, 
unknown isoform) expression in 46 pancreatic cancer patients. The majority of the pan-
creatic tumors (35/46) showed no or faint expression of the IFNAR-α/β, 9 tumors showed a 
moderate expression and only 2 of the pancreatic tumors showed a high expression. The 
expression of the IFNAR-α/β receptor did not correlate with clinical and/or pathological 
parameters. Patients with tumors expressing a high-moderate IFN-α/β receptor had a 
significant better survival compared to patients with tumors with no detectable IFN-α/β ex-
pression (22 months versus 13 months; log rank p=0.012). In addition, patients with tumors 
with a positive receptor expression and whom received adjuvant chemotherapy (n=7) had 
a significant better survival compared to the patients that received adjuvant therapy but 
whose tumors showed no receptor expression (n=25) (24 months versus 14.7 months; log 
rank p=0.012). However, in these studies no distinction was made regarding cancer origin. 
Although periampullary cancers, like ampullary carcinomas and distal bile duct cancers, 
arise in the same anatomical area and are subjected to the same surgical procedure as pan-
creatic cancers, they have different prognosis and distinction between these two cancers is 
of importance3,74.
6.  interferons in the treatment of Pancreatic cancer – clinical 
studies
Similar to most other clinical studies, in the clinical trials with respect to pancreatic cancer, 
IFN-α is the most evaluated type I IFN. The use of IFN-α in the treatment of pancreatic cancer 
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chapter 1was at first evaluated in the palliative setting, later on, as adjuvant treatment. Many differ-
ent treatment strategies combining a variety of chemotherapeutic agents with or without 
radiation therapy and different dosages of IFNs have been tested and will be discussed 
below.
6.1  interferon therapy in the palliative treatment setting
From 1992 until 2000 11 phase II single treatment arm studies were performed using INF-α 
in the treatment of advanced pancreatic cancer16,17,75-83 (Table 2). There was only 1 phase II 
randomized clinical trial15 and only 1 study that explored the effect of IFN-β55(Table 3). In 
the majority of the studies the outcome of interest was the feasibility of IFN therapy, the 
response rate and the related toxicities. Overall, the number of patients included in the 
studies were small, ranging from 6 patients in the study of Moore et al.80 to 57 patients 
in the study of Bernhard et al.75. The chosen treatment regimen included in the major-
ity of the studies included IFN-α and 5-fluoracil (5-FU) combined with inter alia cisplatin 
(CDDP), leucovorin (LV) and/or 13-cis retinoid acid. One study79 also included etoposide, 
a topoisomerase inhibitor, another study added folinic acid to the treatment regimen75. 
The treatment dose of IFN-α ranged from 9 million international units (IU) a week up to 6 
million IU daily. In the palliative setting the median survival ranged from 4.6 to 11 months. 
Treatment toxicities were in most of the studies of gastrointestinal and/or hematological 
origin. Only a few studies showed the proportion of patients experiencing treatment toxici-
ties75,76,79-81,83. Solely the study of MacDonald et al79 reported a case of complete response, 
implying the disappearance of tumor mass, on IFN-α therapy. A partial response, in most of 
the studies defined as a reduction of tumor mass greater than 50%, was variably, though 
not extensively, observed in the majority of the studies. Despite the fact that in all studies 
most of the patients did not show a reduction in tumor mass, in some patients the disease 
did remained stable for a, unfortunately not specified, period of time on IFN-α therapy.
The randomized clinical trial of Wagener et al15 aimed to demonstrated an effect of 
IFN-α on rate and the duration of response. In total, 33 patients were randomized to either 
the CDDP+5-FU arm (18 patients) or the CDDP+5-FU+INF-α arm (15 patients). Median 
survival was not different between the two groups (6.5 versus 5 months) and treatment 
related toxicity were in both arms considerable. In the CDDP/5-FU arm there were no partial 
responses, 50% of the patients had stable disease with a median time to progression of 
5 months. Although there were two partial responses achieved in the CDDP/5-FU/INF-α 
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table 2. Interferon based therapy in the palliative setting
study year total 
no. 
patients
treatment ifn 
dosage
partial 
response(%)b
grade 
iii/iv 
toxicity 
(%)
stable 
disease(%)
median 
survival 
(months)
Padzur et al.10 1992 49 5-FU+IFN-α2a 3* 9 MIU/
week
4.0 NR 28.5 5.5
Scheithauer 
et al.83
1992 32 5-FU+LV+IFN-
α2b
3* 10 MIU/
week
12.5 9.3b 40.5 5.5
Moore et al.81 1993 22 5-FU+LV+IFN-
α2a
3* 3 MIU/
week
14.0 73b 18.0 NR
Bernhard et 
al.75
1995 57 5-FU+FA+IFN-
α2a
1* 6 MIU/
week
14.0 28b 49.0 10.0
Moore et al.80 1995 6 13-cis RA+IFN-
α2a
1* 6 MIU/
daily
0.0 16b NR NR
Sparano et 
al.9
1996 26 5-FU+IFN-α2b 3* 5 MIU/
m2/week
8.0 NR NR 4.6
Sporn et al.82 1997 18 5-FU+LV+CDDP 
+IFN-α2b
1* 5 MIU/
m2/daily
37.5 NR NR 5.0
John et al.78 1998 13 5-FU+IFN-α 3* 3 MIU/
week
1.0 NR NR 8.0
Brembreck 
et al.76
1998 26 13-cis RA+IFN-
α2a
1* 6 MIU/
week
4.5 13.6c 63.6 7.7
Recchia et 
al.55
1998 23 Epirubicin+ 
Mitomycin C+ 
racemic FA+ 
5-FU+IFN-β+ 
retinol palmitate
3* 1 MIU/
week
26.0 NR 35.0 11.0
MacDonald 
et al.79
2000 55 Etoposide +
5 -FU+LV+IFN-
α2b
3* 3 MIU/
week
9.0 32.7d 27.2 5.0
David et al.77 2000 23 5-FU+LV+IFN-
α2a
5* 5 MIU/
week
0.0 NR 17.0 NR
Wagener 
et al.8
2002 15a CDDP+5-
FU+IFN-α2b
5* 3 MIU/
week
2.0 46.6 46.6 5.0
IFN, interferon; LV, leucovorin; FA, folinic acid; 13-cis RA, 13-cis retinoid acid; CDDP, cisplatin; NR, not reported;
a A total of 33 patients were randomly assigned to IFN-α based therapy or 5-FU+ cisplatin based chemotherapy. 
OS of patients in the 5-FU+cisplatin treatment arm (6.5 months) was not significantly different from patients in 
the IFN-α based treatment arm.
b Partial response was overall defined as 50% or greater reduction in the bidimensional product of the tumor 
mass for at least 4 weeks or one interval with no appearance of new disease.
c All grade III events
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arm, only 46.6% of the patients had stable disease with a median time to progression of 3 
months.
Only one phase II non-randomized clinical study explored the effect of IFN-β in the 
treatment of advanced pancreatic carcinoma55. In this study 23 patients received a treat-
ment regimen of epirubicin, mitomycin C, racemic folinic acid, 5-FU, retinol palmitate and 
IFN-β. The median survival was 11 months and the progression free survival was 7.5 months. 
Treatment toxicity was mainly hematological (leukopenia, thrombocytopenia and anemia). 
table 3. Interferon based therapy in the adjuvant treatment setting
study year total no. 
patients
treatment ifn dosage median 
survival 
(months)
2-year 
survival 
(%)
dfs 
(months)
grade 
iii/iv 
toxicity 
(%)
Nukui et al.4 2000 17 EBRT 
+5-FU+CDDP+ 
IFN-α
3* 3 MIU/
every other 
day
>24.0b 84.0 NR 53.0
Picozzi et al.6 2003 43 EBRT 
+5-FU+CDDP+ 
IFN-α
3* 3 MIU/
every other 
day
44.0 64.0 16.0 70.0
Linehan et 
al.85
2008 22 EBRT 
+5-FU+CDDP+ 
IFN-α
3* 3 MIU/
week
25.0 56.0 25.0 68.0
Nitsche et 
al.84
2008 11 EBRT 
+5-FU+CDDP+ 
IFN-α
3* 3 MIU/
week
NR 55.0 NR 73.0c
Picozzi et al.5 2010 80 EBRT 
+5-FU+CDDP+ 
IFN-α2b
3* 3 MIU/
week
36.0 59.0 14.1 95.0
Katz et al.3 2011 28 EBRT 
+5-FU+CDDP+ 
IFN-α2b
3* 3 MIU/
week
42.0 79.0 28.9 89.0c
Schmidt et 
al.7
2012 53a EBRT 
+5-FU+CDDP+ 
IFN-α2b
3* 3 MIU/
week
32.1 62.0 15.2 85.0
DFS, disease free survival; EBRT, external-beam radiotherapy; CDDP, cisplatin; IFN, interferon; FA, folinic acid; 
MIU, million international units; NR, not reported;
a A total of 110 patients were randomly assigned to IFN-α based chemoradiation or systemic 5-FU+FA based 
chemotherapy. OS of patients in the 5-FU treatment arm (28.5 months) was not significantly different from 
patients in the IFN-α based treatment arm.
b Median survival not calculated as 67% of the patients were still alive at time of report.
c All grade III events, no grade IV events observed
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Complete response was achieved in 9% of the patients; a partial response was achieved in 
26% of the patients and 35% of the patients showed stable disease on the treatment.
Unfortunately, only a few conclusions can be drawn from the above-discussed studies. 
The majority of the studies are single treatment arm studies in which only 2 studies showed 
a case of complete response on IFN therapy. In addition, in all studies treatment toxicities 
were considerable. In the only randomized clinical study partial responses were observed, 
and treatment toxicities were similar among the two treatment arms, unfortunately this did 
not translate into a (progression free) survival benefit for patients in the experimental arm 
of the study. Based on these findings, until more advanced and better-designed studies are 
developed, IFN-α therapy in the palliative setting is not preferred.
6.2  adjuvant interferon-α therapy
In the adjuvant treatment setting of pancreatic cancer, from 2000 until 2012, 6 phase II 
IFN-α based clinical studies10-13,84,85 and one phase III randomized clinical trial14, have been 
conducted (Table 3). In all of the studies the added value of concomitant IFN-α to external 
beam radiation therapy (EBRT), 5-FU and cisplatin was explored. In total, the outcome of 
interest was overall survival, toxicity and in some studies quality of life. The study of Katz 
et al10. reported the highest median survival of 42 (32.1-64.5) months with a 2-year and 
5-year survival of 79% and 35%, respectively. Picozzi et al13 reported a 5-year survival of 55% 
of patients receiving adjuvant IFN-α therapy. Additionally, high overall survival rates were 
described by the other studies as well. Nevertheless, grade III and IV treatment toxicities, 
mostly from gastrointestinal and hematological origin, were in all studies considerable and 
ranged from 53% in the study of Nukui et al11 up to 95% in the study of Picozzi et al12. In the 
study of Nitsche et al85. and Katz et al10. no grade IV toxicity was observed.
The only randomized clinical trial was performed by Schmidt et al14. at the university of 
Heidelberg in which a total of 110 patients were randomized to either the experimental arm 
of the study (53 patients) receiving 5-FU, cisplatin, IFN-α and radiotherapy, or to the 5-FU 
monotherapy arm (57 patients). The total follow up duration was 45.9 months. The median 
survival for patients randomized to the experimental IFN-α arm was 32.1 months (95% CI 
22.8 to 42.2 months) and for patients in the monotherapy arm 28.5 months (95% CI, 19.5 to 
38.6 months) which was not statistically significant different. Although the survival of pa-
tients receiving IFN-α did not improve significantly compared with 5-FU monotherapy, the 
difference in median survival of 3.6 months implies that some patients probably benefited 
from the experimental treatment. Furthermore, grade III and IV toxicity was experienced in 
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chapter 185% and 16% of the patients in the experimental arm and in the monotherapy arm, respec-
tively, although the difference cannot only be attributed to the addition of IFN-α.
Despite the strong evidence that IFN-β has more potent anticancer features compared 
to IFN-α, no clinical studies have been conducted regarding adjuvant IFN-β therapy in 
pancreatic cancer.
7.  aims and outlines of this thesis
As indicated in the previous paragraphs, in addition to the antiviral and immunoregulatory 
activities, type I interferons are also able to inhibit cell proliferation, induce apoptosis, block 
cell cycle and sensitize tumor cells for chemo- and radiotherapy. In pancreatic cancer, sev-
eral studies, including some clinical studies, demonstrated promising, although variable, 
results of (adjuvant) interferon (predominantly IFN-α) therapy. However, several important 
aspects of type I interferon therapy, like the importance of receptor expression, the influ-
ence of growth factors and the use of IFN-β, remain underexposed. Therefore, the main aim 
of this thesis is to further elucidate the role of type I interferon therapy in the treatment of 
pancreatic cancer.
The first aim was to evaluate the relationship between type I interferon receptor ex-
pression (IFNAR-1 and IFNAR-2c) and the antitumor effect of IFN-α and –β in vitro (chapter 
2). The second aim of this thesis was to determine the influence of insulin and insulin-like 
growth factors on the proliferation and migration of human pancreatic cancer cells and 
to investigate to what extent IFN-β is capable of inhibiting the basal- and growth factor 
stimulated cell proliferation and migration (chapter 3). The third aim of this thesis was to 
investigate the role of IFN-β therapy alone and in combination with gemcitabine in vivo 
(chapter 4). The fourth aim of this thesis was to determine the expression of the IFNAR-1 
and IFNAR-2c receptor in human pancreatic cancer specimens and to investigate whether 
interferon receptor expression is associated with clinicopathological factors and survival 
(chapter 5). Finally, the experimental findings of this thesis and some future perspectives 
will be discussed (chapter 6).
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abstract
background: Pancreatic cancer is a highly aggressive malignancy with limited treatment 
options. Type I Interferons (e.g. IFN-α/-β) have several anti-tumor activities. Over the past 
few years clinical studies evaluating the effect of adjuvant IFN-α therapy in pancreatic 
cancer yielded equivocal results. Although IFN-α and -β act via the type I IFN receptor, the 
role of the number of receptors present on tumor cells is still unknown. Therefore, this study 
associated, for the first time, in a large panel of pancreatic cancer cell lines the effects of 
IFN-α/-β with the expression of type I IFN receptors.
methods: The anti-tumor effects of IFN-α or IFN-β on cell proliferation and apoptosis were 
evaluated in 11 human pancreatic cell lines. Type I IFN receptor expression was determined 
on both the mRNA and protein level.
results: After 7 days of incubation, IFN-α significantly reduced cell growth in 8 cell lines by 
5-67%. IFN-β inhibited cell growth statistically significant in all cell lines by 43-100%. After 3 
days of treatment, IFN-β induced significantly more apoptosis than IFN-α. The cell lines vari-
ably expressed the type I IFN receptor. The maximal inhibitory effect of IFN-α was positively 
correlated with the IFNAR-1 mRNA (p<0.05, r=0.63), IFNAR-2c mRNA (p<0.05, r=0.69) and 
protein expression (p<0.05, r=0.65) expression.
conclusion: Human pancreatic cancer cell lines variably respond to IFN-α and -β. The 
expression level of the type I IFN receptor is of predictive value for the direct anti-tumor 
effects of IFN-α treatment. More importantly, IFN-β induces anti-tumor effects already at 
much lower concentrations, is less dependent on interferon receptor expression and seems 
therefore more promising than IFN-α.
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1.  introduction
Pancreatic cancer is the fourth leading cause of cancer related death in the western world1. 
Surgery is the only curative therapy but due to early metastases and local invasion only 
15-20% of the patients are eligible for resection at time of presentation. After resection 
prognosis remains poor resulting in an overall 5-year survival for patients diagnosed with 
pancreatic cancer of less than 5%. Several larger clinical studies have suggested the benefit 
of adjuvant therapy; however no definite consensus about the optimal treatment regime 
has been established 2-5. To further improve survival, research has focussed on new and 
other medical treatment options, like adding biological modulators as interferon6-8.
Interferons (IFNs) are known to have antiproliferative, antiviral and immunoregulatory 
activities. Type I IFNs (e.g. IFN-α, IFN-β and IFN-ω) are also involved in cell differentiation and 
anti-tumor defence processes, and besides that they are also able to sensitize tumor cells 
for chemo- and radiotherapy 9-11. Type-I IFNs act via the type-I IFN receptor complex which 
is composed by two subunits; IFNAR-1 and IFNAR-2, of which there are three isoforms that 
are differently spliced from a common gene. IFNAR-2a is the soluble form and can act as 
a dominant negative regulator of free IFNs, IFNAR-2b is a shorter form lacking regions of 
the cytoplasmic domain and unable to activate JAK-STAT signaling once the receptor binds 
IFNs. IFNAR-2c contains the entire cytoplasmic domain and along with IFNAR-1 makes 
up the functional IFN receptor complex, capable of binding IFNs and inducing JAK-STAT 
signaling 12,13. Currently, IFN-α is used in the treatment of several malignancies like chronic 
myeloid leukaemia, metastatic melanoma, renal cell carcinoma and Kaposi sarcoma 14,15. 
IFN-β is only used in the treatment of multiple sclerosis 16.
In experimental models in vitro and in vivo, the anti-tumor effect of IFN-α has been 
demonstrated 11,17-21 and in the past years a number of clinical studies have been conducted 
regarding adjuvant IFN-α therapy. The study of Picozzi et al. 7 reported an actuarial 5-year 
survival of 55%, but regrettably none of the other studies achieved an overall survival that 
high and also treatment toxicities were very high 6,8.
Surprisingly, very few studies investigated the effect of IFN-β, even though some in 
vitro studies showed that IFN-β binds the receptor complex with a higher affinity and has 
greater anti-tumor effects than IFN-α 11,17,18,22. Despite the fact that the approximate amount 
of receptors may determine the effect 10, the relationship of type I IFNs receptor expres-
sion with the anti-tumor effect of IFN-α/β in pancreatic cancer cell lines is not established. 
Therefore, in the present study we evaluated the anti-tumor activity of IFN-α and IFN-β in 
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11 human pancreatic adenocarcinoma cell lines and assessed the correlation between the 
responsiveness to type I IFNs and the expression of IFNAR-1 and IFNAR-2c receptors.
2.  materials and methods
2.1  cell lines and culture conditions
The human pancreatic cell lines AsPC-1, BxPC-3, Capan-1, Capan-2, CFPAC-1, HPAF-II, Hs 
700T, Hs 766T, MIA PaCa 2, PANC-1 and SU.86.86 were obtained from the American Type Cul-
ture Collection (Rockville, MD, USA). All cell lines were allelotyped and the DNA (STR) profile 
corresponded with the profile of the ATCC. The cells were cultured in a humidified incubator 
at 5% CO2 and 37°C. The culture medium consisted of RPMI 1640 supplemented with 5% 
FCS, penicillin (1x105 U/L) and L-glutamine (2 mmol/l). Capan-1, Capan-2 and SU.86.86 were 
cultured in medium consisting of RPMI 1640, supplemented with 10% FCS, penicillin (1x105 
U/L) and L-glutamine (2 mmol/l). Periodically, cells were confirmed as Mycoplasm-free. Cells 
were harvested with trypsine (0.05%) EDTA (0.53 mM), counted microscopically using a 
standard haemocytometer, resuspended in medium and plated in 24-well multiwell plates. 
Trypan blue staining was used to asses cell viability. Media and supplements were obtained 
from GIBCO Bio-cult Europe (Invitrogen, Breda, The Netherlands).
2.2  drugs and reagents
Human recombinant IFN- α-2b (Intron-A) was obtained from Schering-Plough Corporation 
(Utrecht, The Netherlands), while human recombinant IFN- β-1a was acquired from Serono 
Inc. (Rebif, Rockland, MA). All compounds were stored at -20ºC and stock solutions were 
constituted in distilled water according to the manufacturer’s instruction.
2.3  cell proliferation assay
For each cell line the optimal cell number plating density was determined (data not shown). 
After trypsinization, the cells were plated in 1 ml of medium in 24 well plates at the correct 
cell density. The plates were placed in a 37ºC, 5% CO2 incubator and cells were allowed 
to attach overnight. The next day increasing concentrations (0-1000 IU/ml) of IFN-α or 
IFN-β were added. Each treatment was performed in quadruplicate. After 3 and 7 days of 
treatment, the cells were harvested for DNA measurement. For the 7-day experiments, the 
medium was refreshed after 3 days and compounds were added again. Measurement of 
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total DNA contents was performed using the bisbenzimide fluorescent dye (Hoechst 33258) 
(Boehring Diagnostics, La Jolla, CA) as previously described 23.
2.4  Quantitative rt-Pcr
For the detection of interferon receptors (IFNAR-1, IFNAR-2 total, IFNAR-2b and IFNAR-
2c) and the housekeeping gene hypoxanthine phosphoribosyltransferase (HPRT), mRNA 
expression was evaluated by quantitative RT-PCR in all 11 pancreatic adenocarcinoma cell 
lines.
The isolation of total RNA (tRNA), complementary DNA (cDNA) synthesis and the primer 
and probe sequences that were used for the detection of IFNAR-1, IFNAR-2 total, IFNAR-2b, 
IFNAR-2c and HPRT have been described previously. The soluble form of IFNAR-2a subunit 
was calculated indirectly by subtracting IFNAR-2b and IFNAR-2c from IFNAR-2 total. 24. All 
the primer and probe sequences were purchased from Biosource (Nivelles, Belgium). The 
primer set that was used to detect an interferon response (interferon stimulated gene 56; 
ISG56) was purchased from Applied Biosystems (Hs00356631).
Dilution curves were constructed for calculating the PCR efficiency for every primer set 
and have been described by Koetsveld et al. 24. After efficiency correction of target and 
reference gene transcripts (HPRT), the comparative threshold method, 2-ΔCt was used to 
calculate the relative expression of genes 25. Interferon treatment did not change HPRT 
mRNA expression. As a positive control for the PCR reactions of HPRT and type I IFN recep-
tors human cDNA of human carcinoid tumor cells was amplified in parallel with the cDNA 
samples26.
2.5  Protein extraction
After trypsinization the cells were plated in 2 ml of medium in 6 well plates and placed in a 
37ºC, 5% CO2 incubator and allow to grow until a confluence of 90% was observed.
Cells were washed with ice-cold PBS. Whole-cell lysates were prepared by adding 200 µl 
ice-cold RIPA lysis buffer (Pierce Biotechnology, Inc., Rockford, IL, USA.) with the addition of 
1% Halt Phosphatase Inhibitor Cocktail (Pierce Biotechnology, Inc.) to each well and incu-
bated for 1 minute on ice. Cell lysates were transferred to labeled tubes and incubated for 
15 minutes on ice (mixing every 5 minutes) and spun down at 18 000xg at 4°C. Supernatants 
were stored at -80°C.
With the dye-binding assay (Bio-Rad Protein Assay) the total amount of protein was cal-
culated. BSA was used as standard curve and a spectrophotometer set to 595 nm as reader.
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2.6  Western blotting
Total protein solution (50µg) diluted in a water solution containing 25% SDS sample buffer 
was denatured (2-3 minutes in a bath at 95°C) and separated by electrophoresis on 10% 
SDS-page gel. After electrophoresis, proteins were transferred onto a nitrocellulose mem-
brane. The membranes were blocked in 0.1% Tween 20-PBS/ 3% non-fat dry milk for 1h and 
incubated overnight at 4°C with the primary antibody (human IFNAR1 (mouse monoclonal 
antibody; Sigma-Aldrich; concentration 1:1000) and human IFNAR2c (monoclonal antibody 
27D11, kindly provided by Dr. E. Croze, International Review of Investigational Science, 
San Francisco Bay Area, USA; concentration 1:700)). After 3 times 5 minutes washing in 
0.1% Tween 20-PBS the membranes were incubated, for 1h at room temperature, with the 
secondary antibody (Alexa Fluor® goat anti-mouse IgG, Invitrogen; concentration 1:15000). 
Starting from the incubation with the secondary antibody membranes were kept in dark 
condition. After the incubation with the secondary antibody, membranes were washed 
twice 5 minutes with 0.1% Tween 20-PBS and finally once 5 minutes with only PBS.
Using the odyssey infrared imaging system (LI-COR Biosciences, Cambridge, UK) im-
munodetection was performed. The optical density of the sized bands was measured using 
the Odyssey molecular imaging software (LI-COR Biosciences). Relative expression of total 
IFNAR-1 or IFNAR-2c was calculated as a ratio to the expression of beta-actin.
2.7  dna fragmentation (apoptosis)
Cells were plated, according to the optimal plating density of each cell line, in 1ml of 
medium in a 24-well plate and allowed to attach overnight. The next day, medium was 
replaced with 1ml fresh medium containing 1000 IU/ml IFN-α or IFN-β. Each treatment was 
performed in quadruplicate. After 3 days of treatment, apoptosis was measured using a 
commercially available ELISA kit (Cell death detection ELISAplus, Roche Diagnostics GmbH, 
Penzburg, Germany) according to manufacturer’s instructions. Apoptosis was expressed as 
percentage of control (untreated) cells, and data was corrected for the total DNA content 
in each well.
2.8  staining of apoptotic cells
Cells were plated and treated in the same manner and order as in the DNA fragmentation 
section, described above. After 3 days of treatment cells were washed twice with PBS and 
fixed for 10 minutes with methanol/acetic acid (3:1). After fixation, cells were washed 
twice with distilled water and incubated for 8 minutes with 5µg/ml Hoechst 33258 (Sigma-
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Aldrich, Zwijndrecht, the Netherlands). After the incubation cells are washed again twice 
with distilled water and apoptotic cells were evaluated under fluorescence microscope 
(Axiovert 200M, HXP 120 external lamp). Cells with condensed or fragmented chromatin 
were considered apoptotic 27.
2.9  statistical analysis
All experiments were carried out at least twice, with exception of the western blot, and 
gave comparable results. For statistical analysis GraphPad Prism 5.0 (GraphPad software, 
San Diego, CA) was used. Concentrations that induced 50% growth inhibition (IC50) and 
maximal inhibitory effects were calculated using non-linear regression curve fitting pro-
gram. The comparative statistical evaluation among groups was performed by a one-way 
ANOVA test. When significant differences were found, a comparison between groups was 
made using the Newman-Keuls test. The unpaired student t-test was used to analyze dif-
ferences in concentration-effect curves (IC50 and maximal inhibitory effect (Emax)). After 
log-log transformation the results were normally distributed and correlation analyses were 
performed using Pearson’s coefficients. In all analyses, values of P<0.05 were considered 
statistically significant. Data are reported as mean ±SEM.
3.  results
3.1  antiproliferative effect of type i ifns
After 7 days of incubation, IFN-α significantly suppressed the growth in 8 of the 11 cell lines, 
IFN-β significantly suppressed the growth of all the cell lines (table 1). The effects of both 
type I IFNs were time- and dose- dependent. The maximal inhibition of cell proliferation 
induced by both compounds was significantly higher after 7 days, compared to 3 days of 
incubation (data not shown). Furthermore, the overall growth inhibitory effect of IFN-β after 
7 days was significantly more potent than the growth inhibitory effect of IFN-α (P<0.0001). 
Figure 1 illustrates 3 cell lines, AsPC-1, Capan-1 and PANC-1, which represent the spectrum 
of effects of IFN-α/-β treatment in the 11 cell lines. In addition, the maximal inhibitory effect 
of IFN-α is correlated with the maximal inhibitory effect of IFN-β (p<0.05 r=0.61).
3.2  effect on apoptosis of type i ifns
To evaluate the effect of type I IFNs on apoptosis, we first measured the percentage of DNA 
fragmentation after 2, 4, 8, 24, 48 and 72u of incubation with 1000 IU/ml IFN-α or 1000 IU/
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table 1. IC50 and maximal inhibitory effect (Emax) of 11 pancreatic adenocarcinoma cell lines after 7 days 
of incubation with IFN-α and IFN-β.
Cell lines
alpha beta
IC50 (IU/ml) Emax (%) IC50 (IU/ml) Emax (%)
AsPC-1 > 1000 38 ± 3.3 *** 272 68 ± 1.7 ***
BxPC-3 > 1000 20 ± 4.2 * 114 89 ± 2.3 ***
Capan-1 378 67 ± 3.6 *** 70 96 ± 1.2 ***
Capan-2 > 1000 10 ± 3.6 >1000 43 ± 2.9 ***
CFPAC-1 841 54 ± 2.6 *** 131 100 ± 1.5 ***
HPAF-II > 1000 21 ± 4.3 *** 192 94 ± 2.0 ***
HS 700T > 1000 5 ± 4.2 272 62 ± 1.8 ***
Hs 766T > 1000 17 ± 3.2 ** 169 76 ± 1.7 ***
MIA PaCa2 > 1000 14 ± 3.6 * 422 75 ± 1.4 ***
PANC-1 > 1000 11 ± 2.9 710 54 ± 5.3 ***
SU.86.86. > 1000 17 ± 2.3 *** >1000 44 ± 2.4 ***
378 - >1000†  25 ± 3.4 70 - >1000† 73 ± 2.2
* p<0.05, ** p<0.01 and ***p<0.001 versus control.
The IC50 is expressed as the concentration needed for 50% of cell growth reduction; concentrations that 
exceeded 1000 IU/ml were mentioned as > 1000. Mean IC50 of IFN-α and –β is expressed as the range†.
The maximal inhibitory effect is expressed as the percentage inhibition compared with the untreated 
control ± SEM.
figure 1. Treatment effects on cell proliferation after 7 days of incubation with increasing concentrations 
of IFN-α and IFN-β in 3 human pancreatic cancer cell lines. Values are expressed as the percentage of con-
trol and represent the mean ± SEM of at least 2 independent experiments in quadruplicate
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ml IFN-β in the relatively sensitive cell line BxPC-3 (data not shown). After 8h of incubation 
the effect of IFN-β on apoptosis became apparent. Starting from 24h the effect of IFN-α and 
IFN-β on DNA fragmentation was already significant and continued to increase significantly 
up to 72h of interferon incubation (p<0.05). Since BxPC-3 is a relatively sensitive cell line 
and because the effect of IFN-α is less pronounced than the effect of IFN-β, we decided 
to measure the amount of induction of DNA fragmentation of the remaining 11 cell lines 
only after 72h (Figure  2a). In total, of the 11 cell lines, 4 cell lines showed, compared to 
the untreated control, a significant increase of DNA fragmentation after 1000 IU/ml of 
IFN-α treatment (CFPAC-1 and HS 700T p<0.05; BxPC-3 and HPAF-II p<0.01). After 3 days 
of IFN-β treatment (1000 IU/ml), 8 of the 11 cell lines showed a significant increase in DNA 
fragmentation (p<0.001; only HS 700T p<0.01). Only Capan-2, Panc-1 and SU.86.86 did not 
show a significant increase in DNA fragmentation after 3 days of IFN-α nor IFN-β treatment. 
In addition, the maximal effect of IFN-α on DNA fragmentation was significantly correlated 
with the maximal effect on DNA fragmentation of IFN-β (p<0.001, r=0.87). Moreover, the 
a b
figure 2a: Effects of IFN-α (greys bars) and IFN-β 
(white bars) treatment on apoptosis (DNA frag-
mentation) in 11 human pancreatic cancer cell 
lines. The cells were incubated for 3 days with 1000 
IU/ml of IFN-α or IFN-β. Values are absorbance units 
and are expressed as the percentage of change in 
DNA fragmentation compared to control. Data are 
the mean ± SEM of at least 2 independent experi-
ments in quadruplicate. * p<0.05, ** p<0.01 and 
***p<0.001 versus control.
figure 2b: Visualisation of apoptosis (nuclear con-
densation, fragmentation and forming of apop-
totic bodies) with Hoechst 33258 after 3 days with-
out treatment (A,D,G), IFN-α (B, E, H) or IFN-β (C, F, 
I) treatment in Capan-1 (A-C), CFPAC-1(D-F) and 
PANC-1 (G-I).The red arrows indicate condensated 
or fragmented nuclei or apoptotic bodies. Original 
magnification x200.
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maximal inhibitory effect of IFN-β on proliferation was significantly correlated with the 
maximal effect of IFN-β on DNA fragmentation (p<0.05, r=0.65).
Besides the quantitative measurement of DNA fragmentation we also visualized, in all 
11 cell lines, nuclear condensation, fragmentation and apoptotic bodies with the Hoechst 
33258 staining. Figure 2b shows the Hoechst staining of Capan-1 a cell line with much DNA 
fragmentation, the PANC-1 a cell line with very little DNA fragmentation as well as CFPAC-1, 
a cell line with an intermediate increase of DNA fragmentation, after IFN-α/-β treatment. 
The Hoechst 33258 staining of the three cell lines that is shown was in accordance with the 
DNA fragmentation measurement, this also applied to the remaining 8 cell lines (data not 
shown).
3.3  expression of type i ifn receptor mrna
We analyzed the receptor mRNA expression of type I IFNAR by quantitative RT-PCR in the 11 
pancreatic adenocarcinoma cell lines. As shown in Figure 3a, all cell lines expressed IFNAR-1 
and IFNAR-2, but with great variability. IFNAR-1 expression was considerably higher (on 
the average 3.6-fold) than IFNAR-2 total (sum of IFNAR2a, IFNAR2b and IFNAR2c isoforms) 
expression. The expression of the IFNAR-2 total was significantly correlated with both the 
expression of the IFNAR-2b (p<0.0001, r=0.92) and the IFNAR-2c (p<0.005, r=0.78). Further-
more, the expression of the IFNAR-1 mRNA is significantly correlated with the expression of 
the IFNAR-2c (p<0.05, r=0.66). Doubling time varied between cell lines (between 28.81 and 
48.26 hours). No significant correlations were found between doubling time and IFNAR-1 or 
IFNAR-2 expression (data not shown).
3.4  Western blotting
Since receptor mRNA expression does not necessarily correlate with receptor expression at 
the protein level, we also characterized the receptor expression at protein level by western 
blotting. The IFNAR-1 and IFNAR-2c are both expressed at an anticipated28,29 band of ~100 
kDA (Figure 3b right panel; arrowhead)although with great variability in the level of protein 
expression (Figure 3b, left panel). The expression of the IFNAR-1 was in all of the cell lines 
on average 17-fold higher than the expression of the IFNAR-2c. The mRNA expression of 
the IFNAR-1 did not correlate with the expression of the IFNAR-1 at the protein level. On 
the other hand, the receptor expression of the IFNAR-2c subunit at mRNA level showed a 
significant positive correlation with the receptor expression of the IFNAR-2c at protein level 
(p<0.05 r= 0.69).
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figure 3a: Relative expression of IFNAR-1, IFNAR-2a, IFNAR-2b and IFNAR-2c mRNA in 11 human pancre-
atic adenocarcinoma cell lines, normalized to HPRT mRNA. Values represent mean ± SEM;
b
figure 3b: Right panel: Western blot analysis of high and low IFNAR-1 and IFNAR-2c protein expression in 
2 human pancreatic cancer cell lines Both IFNAR-1 and IFNAR-2c are expressed at approximately 100 kDa, 
previously reported to be the main Mw of both IFNAR receptors. b-actin is expressed at 42 kDa. (M=marker, 
1.Capan-1, 2. MIA PaCa-2) Left Panel; IFNAR-1 (left axis, white bars) and IFNAR-2c (right axis, grey bars) 
protein band density relative to b-actin band density in 11 human pancreatic adenocarcinoma cell lines.
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3.5  correlation of the receptor expression with the anti-proliferative effect of 
type i ifns
Amongst the panel of human pancreatic cancer cell lines we found a considerable variation 
in their sensitivity to type I IFNs. Considering the fact that there was also a lot of variation 
in the expression of the receptor complex of IFNAR-1 and IFNAR-2c, which is responsible 
for initiating signal transduction, we determined the relationship between the maximal 
inhibitory effects of IFN-α and IFN-β and the IFNAR-1 and IFNAR-2c mRNA expression levels. 
Overall, only a significant correlation was found between the maximal inhibitory effect of 
IFN-α and the expression of IFNAR-2c (p<0.05, r=0.63).
However, after evaluation of the individual cell lines, there was one cell line that re-
sponded completely different to type I IFNs compared to the other cell lines. For this cell 
line, e.g. Capan-2, it is remarkable that there is a poor response to IFN-α and IFN-β, despite 
the fact that this cell line does express a significant number of IFNAR-1 and IFNAR-2c recep-
tors to initiate an effect. This could be due to a defect in post receptor signal transduction, 
which was illustrated by the fact that there was only a very low up-regulation of ISG56 
after IFN-α (4.47 ± 0.45 fold compared to control) and IFN-β (7.00 ± 0.50 fold compared to 
control) treatment. This was not in line with the amount of up-regulation of ISG56 in the 
BxPC-3 cell line after IFN-α (41.24 ± 12.1 fold) or IFN-β treatment ( 99.47 ± 5.61 fold), a cell 
line with nearly the same amount of IFNAR expressed.
For this reason we excluded Capan-2 from further correlation analysis. Figure 4 and 5 
show the correlations between the growth inhibitory effect of IFN-α and IFN-β and IFNAR 
mRNA and protein expression, respectively, in the remaining 10 cell lines. There was a 
significant correlation between the IFNAR-1 mRNA expression and the response to IFN-α 
(p<0.05, r=0.63) (Figure  4, left upper panel). This correlation was also found regarding 
IFNAR-2c mRNA expression and the response to IFN-α (p<0.05, r=0.69) (Figure 4, right upper 
panel).
Furthermore, there was a significant correlation between the IFNAR-2c mRNA expres-
sion and the IFNAR-2c protein expression (p<0.01, r=0.77). The IFNAR-2c protein expression 
also correlated significantly with the response to IFN-α (p<0.05, r=0.65; Figure 5, right upper 
panel). IFNAR-2a and IFNAR-2b expression did not correlate with the effects of IFN- α or 
IFN-β treatment.
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figure 4: Correlation of the maximal inhibitory effect of IFN-α (1000 IU/mL) and IFN-β (1000 IU/mL) with 
the expression level of IFNAR-1 and IFNAR-2c mRNA in 10 human pancreatic adenocarcinoma cell lines 
(log-log transformed scale). The maximal inhibitory effect is expressed as percentage inhibition com-
pared with untreated control. There was a significant correlation between the expression of IFNAR-1 
mRNA and the maximal inhibitory effect of IFN-α (p<0.05, r= 0.63). A significant correlation was found as 
well between the expression of the IFNAR-2c and the maximal inhibitory effect of IFN-α (p<0.05, r=0.69). 
However there was no significant correlation regarding the maximal inhibitory effect of IFN-β and the 
expression of the IFNAR-1 or IFNAR-2c mRNA.
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4.  discussion
Pancreatic cancer is a highly aggressive malignancy, with very limited treatment outcome. 
The effect of adjuvant treatment modalities like chemo- and radiotherapy are still marginal. 
To improve survival in patients with pancreatic cancer additional treatment options are 
clearly required2,3. Several years ago a number of clinical studies have been conducted 
regarding adjuvant IFN-α therapy in the treatment of pancreatic cancer. Some studies re-
ported a remarkable increase in the 2- and 5-year survival6,7,30. On the other hand, the only 
randomized clinical trial did not show a significant increase in overall survival, although the 
figure 5: Correlation of the maximal inhibitory effect of IFN-α (1000 IU/ml) and IFN-β (1000 IU/ml) with 
the expression of IFNAR-1 and IFNAR-2c at protein level in 10 human pancreatic adenocarcinoma cell lines 
(log-log transformed scale). The maximal inhibitory effect is expressed as percentage inhibition compared 
with untreated control. There was a significant correlation between the expression of IFNAR-2c protein 
and the maximal inhibitory effect of IFN-α (p<0.05, r= 0.65), this correlation was not found for IFN-β. No 
correlation was found between the IFNAR-1 mRNA expression and the maximal inhibitory effect of IFN-α 
or IFN-β.
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increased median survival implicated that some patients in the experimental arm benefited 
from adjuvant IFN-α therapy31. Despite that some in vivo and in vitro studies have investi-
gated the role of type I IFNs, in particular IFN-α in pancreatic cancer, the importance of the 
IFN receptor expression in relation with the effect of type I IFNs is not clarified. Previous 
research of Vitale et al. 17 and Saidi et al. 20,32,33 established a trend towards the importance 
of the IFN receptor in the response of IFN-α and -β, however, the number of cell lines used 
in these studies were very low. Furthermore, despite the fact that some studies did show 
promising results 11,17,18,22, the effect of IFN-β in the treatment of pancreatic cancer still 
remains underexposed. Therefore, in the present study we evaluated the type I IFN receptor 
expression in a large panel of available human pancreatic cancer cell lines and associated 
the receptor expression with the anti-tumor potencies of IFN-α and IFN-β.
In the panel of 11 human pancreatic adenocarcinoma cell lines there was a considerable 
variability in the response to the type I IFNs. Overall, IFN-β is a significantly more potent 
inhibitor of cell proliferation compared with IFN-α. IFN-β inhibited cell proliferation already 
at very low concentrations (10-50 IU/ml) in the majority of the cell lines, which is in agree-
ment with the study of Vitale et al. 17. and Jost et al. 18. The maximal inhibitory effect of 
IFN-α significantly correlated with the maximal inhibitory effect of IFN-β. Consequently, cell 
lines that achieve a higher maximal inhibitory effect with IFN-α will also achieve a higher 
maximal inhibitory effect with IFN-β.
Type I IFNs are also known to induce apoptosis which can act via the intrinsic mitochon-
dria mediated pathway or the extrinsic death receptor induced pathway, both resulting in 
nuclear condensation and fragmentation, followed by fragmentation of the cell into apop-
totic bodies. Both type I IFNs were able to induce apoptosis, however, the increase of DNA 
fragmentation after IFN-β therapy was considerably more potent compared to the increase 
in DNA fragmentation after IFN-α treatment. The increase in DNA fragmentation was also 
visualised by Hoechst 33258 and was consistent with the quantitative DNA fragmentation 
measurements.
By quantitative RT-PCR and western blotting we demonstrated that all pancreatic cell 
lines expressed the IFNAR-1 and IFNAR-2c receptors, although receptor expression levels 
varied considerably. The maximal inhibitory effect of IFN-α was positively correlated with 
the expression of IFNAR-2c. Remarkably, one cell line, Capan-2, did express a significant 
amount of the type I IFN receptor but showed only a marginal response to IFN-α and-β. Type 
I IFNs act via several signalling pathways 34. Like in many different types of cancers, there 
can be a defect in the interferon post receptor signalling pathway, resulting in the absence 
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of an up-regulation of interferon stimulated genes. For this reason, we measured the up-
regulation of ISG56 after IFN-α and IFN-β treatment in the Capan-2 cell line. Compared to 
BxPC-3, Capan-2 showed only very low ISG56 up-regulation. Therefore, a defect in the post 
receptor signalling pathway in Capan-2 is likely. The development of pancreatic cancer 
often occurs through the accumulation of genetic mutations, including frequent mutations 
in the KRAS (Kirsten rat sarcoma viral oncogene homolog), p53, CDKN2A (p16) and SMAD4 
(DPC4)35. The presence or absence of genetic mutations in these cell lines could determine 
the amount of interferon receptors expressed and/or influence the effect of IFN-α and-β. 
The cell lines included in our study displayed a wide variability in genetic alterations. There 
was no difference between wild type and mutated cell lines in their response to IFN-α and-β 
treatment, nor in the number of type I IFNARs. Nevertheless, it is notable thatCapan-2 is the 
only wild type p53 cell line in this panel of pancreatic cancer cell lines. Literature data shows 
that type I IFNs can up-regulate p53 which can initiate apoptotic pathways 36. The fact that 
we did observe an up-regulation of apoptosis in the mutated p53 cell lines, while very little 
induction of apoptosis in the Capan-2 wild type p53 cell line strengthens the concept that 
the Capan-2 cell line has an impaired post receptor interferon signalling pathway. For this 
reason, the Capan-2 cell line was excluded from the further analysis. In the remaining 10 
cell lines there was a significant positive correlation between the IFNAR-1 mRNA, but not 
protein, expression and the maximal inhibitory response to IFN-α. In addition, IFNAR-2c 
mRNA and protein expression showed a positive correlation with the maximal inhibitory 
effect of IFN-α. Our findings in human pancreatic cancer cells endogenously expressing 
the IFNAR-2c add to the observations by Wagner et al.10, who showed in melanoma, breast 
cancer and lung fibrosarcoma cell models that transfection and overexpression of IFNAR-2c 
enhances their sensitivity for type I IFNs in vitro and in vivo. Based on these findings it is 
concluded that the number of IFNAR-2c receptors can be of predictive value in determining 
responsiveness of human pancreatic cancer cells to IFN-α therapy. However, one should 
realize that in selected pancreatic cancers, reflecting our observations in Capan-2 cells, 
defects in IFNAR signalling can occur, rendering such cancers insensitive to IFN treatment.
Although IFN-α and –β act via the same receptor complex, both cytokines display func-
tional differences. In addition to the fact that IFN-α and –β share only 35% of their sequence 
identity and that IFN-β, unlike IFN-α is a glycosylated protein, a study by Johns et al. demon-
strated that IFN-β has a 10-fold higher binding affinity with the receptor complex compared 
to IFN-α37 Moreover, IFN-β induced an up-regulation of 338 genes in human fibrosarcoma 
cells, whereas IFN-α induces an up-regulation of only 130 genes38. A different interaction 
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with the type I IFN receptor complex between IFN-α and –β can be an explanation for the 
more potent activity of IFN-β as well. Recently, an elegant study by de Weerd et al. using 
IFNAR-1 and IFNAR-2 knockout mice, demonstrated that IFN-β can induce functional signal 
transduction, via the IFNAR-1, independently of the IFNAR-2c receptor39. In addition, it 
was found that 104 unique genes were induced by this IFNAR1-IFN-β signalling axis. These 
observations may form an explanation for the lack of correlation between the IFNAR-1 and/
or IFNAR-2c receptors and the maximal inhibitory effect of IFN-β, as we found in our study, 
but also for the much higher potency of the antitumor effects of IFN-β, compared to IFN-α.
Although hypothetical, several potential pathways may be involved in the above indi-
cated differential direct anti-tumor activities of IFN-α and IFN-ß. First, IFN-β may be more 
potent than IFN-α in stimulating the protein kinase dependent on double stranded RNA 
(PKR). PKR is involved in the regulation of protein synthesis and the action of transcription 
factors and is thereby able to control several cellular processes, including cell growth40,41. 
Secondly, IFN-β may be more effective in down-regulating cdk activity or up-regulating 
cdk-inhibitory proteins, as the compound was shown to be more potent than IFN-α in 
inducing cell cycle arrest in human pancreatic cancer cell lines17. Thirdly, fewer or less ef-
fective survival mechanisms may be induced (i.e. up-regulation of the EGFR, stimulation of 
STAT-3, induction of SOCS-1 and -3 or the stimulation of the MAPK cascade;41) after IFN-β 
treatment compared to IFN-α treatment. However, to the best of our knowledge there are 
no studies that made a direct comparison between the effects of IFN-α and IFN-ß on PKR, 
cdk’s and survival pathways in human pancreatic cancer cells.
Regarding IFN-β, the concentration required to reduce cell growth with 50% ranged 
from 70 to over a 1000 IU/ml. These concentrations seem not easily reached in serum of 
human healthy volunteers after s.c. administration (4-10 IU/ml after four doses of 18 MIU 
IFN-β at 48-h intervals)42. However, the recently developed PEGylated form of IFN-β, which 
is currently being tested in phase III clinical trial (ADVANCE) in patients with multiple sclero-
sis seems very promising in this respect. In experimental models, after a single s.c. dose of 
PEG-IFN-β (3.0 MIU/kg in monkeys), serum concentrations of 100 IU/mL were reached after 
20 hours43,44. Although this serum concentration is for some cell lines still not high enough, 
it does get into the sensitivity range to IFN-β of several well responding pancreatic cancer 
cell lines
Our study showed four cell lines in which IFN-α and -β had only a marginal anti-tumor 
effect, but over time an increasing trend in anti-tumor activity was observed. This advocates 
for a longer treatment period, combined with DNA damaging agents like 5-fluorouacil, 
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gemcitabine or radiotherapy. Tomimaru et al. confirms this hypothesis and showed that 
IFN-β combined with gemcitabine was able to induce synergistically anti-tumor effects 
even in the pancreatic cancer cells with low IFN receptor expression22. Taken this together, 
this seems promising and further in vivo research is definitely necessary. Furthermore, the 
interaction of type I IFNs with the cells representing the host immune response cannot be 
neglected as the relevance of cancer immunoediting is becoming clearer 45.
In conclusion, IFN-β is a significant more potent growth inhibitor in pancreatic cancer 
than IFN-α. Although there is a lot of heterogeneity amongst the panel of pancreatic cancer 
cell lines, there is a significant correlation between the expression level of the IFNAR-2c 
receptor and the maximal inhibitory effects of IFN-α. This study provides for the first time 
extensive and well substantiated evidence that the expression of these receptors in pan-
creatic cancer can be of predictive value in the responsiveness to the direct tumor growth 
inhibitory effects IFN-α therapy. More importantly, IFN-β induces a tumor growth inhibitory 
effect already at lower concentrations, is less dependent on receptor status, and seems 
therefore more promising than IFN-α.
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abstract
introduction: Pancreatic cancer is a highly aggressive malignancy with few treatment 
options. The overexpression of several growth factors, including insulin and insulin-like 
growth factors (IGFs), can underlie the aggressive nature of this disease. Previous research 
has demonstrated potent effects of interferon (IFN)-β on pancreatic cancer cell growth, 
however up till now it is unknown whether IFN-β is able to counteract IGF1, IGF2 and 
insulin-induced pancreatic cancer cell proliferation and migration.
methods: Expression of IGF- and insulin receptors was determined and the stimulatory 
effects of IGF1, IGF2 and insulin on cell proliferation and migration, as well as the inhibitory 
effects of IFN-β were evaluated in 3 human pancreatic adenocarcinoma cell lines.
results: Both the insulin- and the IGF1 receptor were variably expressed in the cell lines. 
IGF1, IGF2 and insulin were capable of stimulating cell proliferation in all three cell lines, 
however cell migration was significantly enhanced only in the BxPC-3 cell line. IFN-β sig-
nificantly inhibited IGF1-, IGF2- and insulin-stimulated proliferation in all three cell lines in 
a dose and time dependent manner. Furthermore, in the BxPC-3 cell line IFN-β significantly 
inhibited both basal and IGF1-, IGF2- and insulin-stimulated cell migration.
conclusion: Both IGF1, -2 and insulin were capable of stimulating proliferation and migra-
tion in human pancreatic cancer cells irrespective of the type of receptor expressed. This 
study demonstrates that insulin, in addition to IGF1 and IGF2, may play an important role in 
the progression of pancreatic cancer. Moreover, IFN-β strongly inhibits growth factor stimu-
lated cell proliferation and migration. Our study supports previous findings which have 
suggested that IFN-β can be a potential promising anti-cancer agent in pancreatic cancer.
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1.  introduction
Pancreatic cancer, with an overall 5-year survival of less than 6%, is the fourth leading cause 
of cancer related death in the western world1. At time of presentation over 80% of the pa-
tients are diagnosed with locally advanced or metastatic disease, indicating that pancreatic 
cancer can be considered as a systemic disease2. Several factors, including the overexpres-
sion of growth factors receptors, like insulin and insulin like growth factor (IGF) receptors, 
can underlie the highly aggressive nature of this disease3,4. Additionally, previous research 
reported in 38-64% of the investigated pancreatic cancer specimens an overexpression 
of the IGF1 receptor (IGF1R), which was associated with more proliferating and invasive 
tumors leading to a poorer survival5.
The IGF system is a highly complex system consisting of two growth factors (IGF1 and 
IGF2), two receptors (IGF1R and IGF2R) and six binding proteins (IGFBP 1-6)6. IGFs are very 
similar in function and structure to insulin, produced by the liver and several other tissues 
in response to pituitary growth hormone, and implicated as regulators of cell differentiation 
and cell proliferation in number of cell systems. Both IGF1 and  –2 can interact with the 
IGF1R. However, only IGF2 can bind to the IGF2R, which is a scavenger receptor. Insulin 
signals via the insulin receptors (IRs) of which there are 2 known isoforms, the IR-A and 
IR-B. The IR-B receptor mainly activates the metabolic signaling pathway, whereas signaling 
via the IR-A induces primarily mitogenic effects. Besides that, insulin and IGFs may interact 
with each other’s receptors, although with different affinities7,8. Furthermore, high levels 
of insulin can increase the hepatic IGF1 production by the upregulation of the growth 
hormone receptor (GHR). In addition, insulin may (independent from GH) directly increase 
IGF1 expression in the liver 9.
In cancer tissue in general, IGF1R is frequently overexpressed and in this respect pan-
creatic cancer is not different from other cancers6,10,11. Binding of IGFs to the IGF1 receptor 
induces activation of several pathways including the MAPK and PI3K pathways, which are 
associated with growth, proliferation, migration and the prevention of apoptosis8. Besides 
that, several epidemiological studies have also shown associations between diabetes mel-
litus and hyperinsulinemia on the one hand and an increased risk of cancer on the other 
hand12-14. Although the underlying mechanism still needs to be clarified, insulin and/or 
insulin receptors may play an important role in the development of cancer15.
Although IGFs and their receptors have shown to be of importance in different cancer 
cell features it is, to the best of our knowledge, unknown to what extent IGFs (i.e. IGF1 and 
IGF2) are able of inducing cell migration in human pancreatic cancer cells. Furthermore, in 
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many studies the role of insulin on tumor cell proliferation and migration is underexposed 
even though insulin is closely related to the IGF system.
Moreover, type I IFNs, particularly IFN-β, are able to modulate the IGF system in tumor 
cells by the suppression of endogenous production of IGF2 and by inhibiting the expression 
of the IGF1R16. Type I interferons (e.g. IFN-α and -β) are cytokines that are able to inhibit cell 
proliferation, induce apoptosis, block cell cycle and to sensitize tumor cells for chemo-and 
radiotherapy17. In a recent study, we have demonstrated these anti-tumor effects in hu-
man pancreatic cancer cells, in which the effects of IFN-β were significantly more potent 
compared to IFN-α18. However, it is unclear to what extent IFN-β is capable of inhibiting 
basal and growth factor stimulated cell proliferation and migration.
The aim of the present study is to evaluate the effect of IFN-β on the IGF1-, IGF2- and 
insulin-stimulated proliferation and migration of human pancreatic cancer cell lines.
2.  materials & methods
2.1  cell lines and culture conditions
The human pancreatic cell lines BxPC-3, Hs 766T and PANC-1 were obtained from the 
American Type Culture Collection (Rockville, MD, USA). All cell lines were allelotyped and 
the DNA (STR) profile corresponded with the profile provided by the ATCC. The cells were 
cultured in a humidified incubator at 5% CO2 and 37°C. The culture medium consisted of 
RPMI 1640 supplemented with 5% FCS, penicillin (1x105 U/L) and L-glutamine (2 mmol/l). 
Periodically, cells were confirmed as Mycoplasm-free. Cells were harvested with trypsine 
(0.05%)EDTA (0.53 mM) solution. Before plating, cells were counted microscopically using 
a standard haemocytometer. Trypan blue staining was used to determine cell viability. 
Media and supplements were obtained from GIBCO Bio-cult Europe (Invitrogen, Breda, The 
Netherlands).
2.2  drugs and reagents
IGF1 and IGF2 were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). Human 
recombinant insulin was obtained from Novo Nordisk (Actrapid®, Bagsvaerd, Denmark). Hu-
man recombinant IFN- β-1a was acquired from Serono Inc. (Rebif, Rockland, MA). IGF1, IGF2 
and IFN- β-1a were stored at -20ºC, insulin was stored at 4 ºC. Stock solutions of IGF1 and 
IGF2 were constituted in 0.01M of acetic acid, insulin and IFN-β were constituted in distilled 
water, all according to the manufacturer’s instruction.
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2.3  Quantitative rt-Pcr
By quantitative RT-PCR mRNA expression of IGF1, IGF2, IGF1R, IR-A, IR-B and the housekeep-
ing gene hypoxanthine phosphoribosyltransferase (HPRT), was evaluated. The isolation of 
total RNA, complementary DNA (cDNA) synthesis and the primer and probe sequences 
(Sigma-Aldrich) that were used for the detection of IGF1, IGF2, IGF1R, IR-A, IR-B and HPRT 
have been described previously.16,19-21 Dilution curves were constructed for calculating 
the PCR efficiency for every primer set and have been described by van Adrichem et al21, 
Varewijck et al.20 and Vitale et al.16 After efficiency correction of target and reference gene 
transcripts (HPRT), the comparative threshold method, 2-ΔCt was used to calculate the rela-
tive expression of genes.
2.4  cell proliferation assay
For each cell line the optimal cell number plating density was determined (data not shown). 
After trypsinization, the cells were plated in 1 ml of medium in 24 well plates at the correct cell 
density. The plates were placed in a 37ºC, 5% CO2 incubator and cells were allowed to attach 
overnight. The next day, after washing the plates three times, the culture medium was replaced 
with 1ml/well medium containing 0.5% FCS. Increasing concentrations (1x10-10 – 10-8) of IGF1, 
-2 and insulin were added. Each treatment was performed in quadruplicate. After 3 and 7 days 
of treatment, the cells were harvested for DNA measurement. For the 7-day experiments, the 
medium containing 0.5% FCS was refreshed after 3 days and compounds were added again. 
As previously described, the measurement of total DNA contents was performed using the 
bisbenzimide fluorescent dye (Hoechst 33258) (Boehring Diagnostics, La Jolla, CA)18.
2.5  cell migration assay
The in vitro cell migration was measured by the scratch assay method described by Liang 
et al22, with some modifications. After trypsinization, cells were plated in 2 ml of medium 
in poly-L-lysine coated 12-wells plates and placed in a 37ºC, 5% CO2 incubator. Cells were 
grown until a confluent monolayer was formed. With a 200µl pipet tip a scratch was made 
in the cell monolayer. The debris was removed by washing the cells once with 1ml of growth 
medium and twice with 1ml of medium containing 0.5% FCS. Hereafter, 2ml of medium 
containing 0.5% FCS and the different compounds of interest were added. The ability of 
cells to migrate into the scratch area was assessed after 2, 4, 8 and 24 hours by comparing 
the 0- and 2,4,8 and 24-hour photomicrographs (Zeiss, Axiovert 40c, x50 magnification) of 
4 fixed points along the scratch area. The percentage of non-recovered scratch area was 
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calculated by dividing the non-recovered area after 2, 4, 8 and 24-hours by the initial scratch 
area (t=0) using the image software (http://rsb.info.nih.gov/ij/).
The scratch assay method was compared with a wound healing assay using the Cytose-
lect ™Wound Healing Assay Kit (Cell Biolabs, Inc., San Diego, USA). Briefly, after trypsinization 
cells were seeded in 1ml of growth medium into 24-wells tissue culture plates containing 
inserts and incubated until a monolayer of cells was formed. After removing the inserts from 
the wells, the cells were treated according to the scratch assay method as described above.
2.6  statistical analysis
All experiments were performed at least twice, with the exception of the migration as-
say, which was performed at least three times. For statistical analysis GraphPad Prism 5.0 
(GraphPad software, San Diego, CA) was used. The comparative statistical evaluation among 
groups was performed by a one-way ANOVA test. When significant differences were found, 
a comparison between groups was made using the Newman-Keuls test. In all analyses, 
values of P<0.05 were considered statistically significant. Data are reported as mean ±SEM.
3.  results
3.1  mrna expression.
By quantitative RT-PCR we analyzed the receptor mRNA expression of the IGF1R, IGF1, IGF2, 
IR-A and IR-B (Figure 1). All 3 human pancreatic adenocarcinoma cell lines expressed the 
IGF1R (highest in PANC-1), IR-A (highest in Hs 766T) and IR-B (highest in BxPC-3). None of the 
cell lines expressed detectable levels of IGF1 mRNA (data not shown). IGF2 mRNA was only 
expressed in the PANC-1 and Hs 766T cell lines, but not in the BxPC-3 cell line.
3.2  growth factor stimulated proliferation.
As shown in figure 2, in two of the three cell lines growth factor stimulated proliferation was 
time- and dose dependent. After 3 days of incubation, at a concentration of 10 nM, IGF1 and 
insulin significantly stimulated the cell proliferation in 2 of the 3 cell lines. IGF2 significantly 
increased cell growth after 3 days in all three cell lines (Figure 2, open bars). After 7 days of 
incubation IGF1 and insulin stimulated the cell growth significantly at a concentration of 
10nM, in all three cell lines, whereas IGF2 increased cell proliferation in 2 of the 3 cell lines 
(Figure 2, black bars). Table 1 shows maximal stimulatory effect of 3 and 7 days incubation 
with IGF1, IGF2 and insulin (all at 10nM) in the 3 cell lines.
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figure 1: Relative expression of IGF-1R, IGF2, IRA and IRB mRNA in 3 human pancreatic adenocarcinoma 
cell lines, normalized to HPRT mRNA. Values represent mean ± SEM.
table 1. Maximal stimulatory effect (Emax) of IGF1, IGF2 and insulin in three human pancreatic cancer 
cell lines.
Panc-1 bxPc-3 hs 766t
Emax (%) 3d Emax (%) 7d Emax (%) 3d Emax (%) 7d Emax (%) 3d Emax (%) 7d
igf1 [10nM] 39.1 ± 5.6 *** 54.5 ± 8.6 *** 20.4 ± 4.8 *** 50.4 ± 6.8 *** 18.4 ± 7.58 27.4 ± 7.9 **
igf2 [10nM] 19.7 ± 6.3 * 79.1 ± 17.8 *** 27.5 ± 4.9 *** 44.5 ± 10.5 *** 16.4 ± 5.8 * 1.6 ± 2.9
ins [10nM] 20.2 ± 5.2 * 24.0 ± 6.8 * 44.0 ± 4.6 ***  50.4 ± 8.5 *** 14.2 ± 4.4 23.3 ± 6.9 *
The maximal stimulatory effect is expressed as the percentage stimulation compared to the untreated 
control
± SEM. * p<0.05, ** p<0.01 and ***p<0.001 versus control.
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3.3  basal and growth factor stimulated migration
To assess cell migration the scratch assay method was used in the three cell lines. First, basal 
cell migration was evaluated after 2, 4, 8 and 24 hours (Figure  3a). Although differences 
were relatively small, overall, the BxPC-3 cells migrated the fastest. After 8 hours 22.9% of 
the scratch was closed and after 24 hours closure was 54.7%. In the PANC-1 and the HS 766T 
cell line values were 20.7% and 16.9% after 8 hours, and 43.1% and 49% after 24 hours, 
respectively.
Furthermore, we evaluated the growth factor stimulated migration (Figure 3b). Of each 
compound (IGF1, IGF2 and insulin) a concentration of 10 nM was used and scratch closure 
was assessed after 8 hours to avoid the possibility of involvement of cell growth. Only in 
figure 2: Treatment effects on cell proliferation after 3 days (open bars) and 7 days (black bars) of incuba-
tion with increasing concentrations of IGF1, IGF2 and insulin in 3 human pancreatic cancer cell lines. Val-
ues are expressed as the percentage of control and represent the mean ± SEM of at least 2 independent 
experiments in quadruplicate * p<0.05, ** p<0.01 and ***p<0.001 versus control.
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the BxPC-3 cell line a statistically significant increase in migration by all growth factors was 
observed (p<0.001). After stimulation with IGF1, 8 hours after scratch 48.2% of the wound 
was closed (76.4% increase compared to control). After stimulation with IGF2 and insulin 
scratch closure was 41.2% and 41.7%, respectively (50.8% and 52.7% increase compared to 
control, respectively).
a
b
figuur 3
a: Left panel: Percentage cell migration in 3 human pancreatic cancer cell lines, after 2, 4, 8 and 24 hours 
after scratch. After scratch, medium was removed and cells were placed in medium containing only 0.5% 
FCS. The percentage of non-recovered wound area was calculated by dividing the non-recovered area 
after 2,3,8 and 24 hours by the initial wound area at 0 time; Right panel: Pictures of the scratch at 0 time 
and 8 and 24 hours after the scratch in 3 human pancreatic cancer cell lines. Original magnification x50;
b. Percentage of cell migration after 8 hours of incubation with 10nM IGF1, IGF2 or insulin in 3 human 
pancreatic cancer cell lines. Values are expressed as the percentage of wound closure compared to 0 time 
and represent the mean ± SEM of at least 3 independent experiments in triplicate, ***p<0.001 versus 
control.
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In addition, to validate the scratch assay, the Cytoselect ™Wound Healing Assay was 
used in the BxPC-3 cell line. No significant differences were observed between the two as-
says regarding basal and IGF1 stimulated cell migration (data not shown).
3.4  inhibition of growth factor stimulated proliferation by ifn-β
We evaluated the effect of two different concentrations of IFN-β on the IGF1 (10nM)-, 
IGF2 (10nM)- and insulin (10nM)-stimulated proliferation after 3 and 7 days of incubation. 
Figure 4 illustrates the effects of 100 and 1000 IU/ml IFN-β, the maximal stimulatory effect 
of IGF1, -2 and insulin, as well as the combined effects of the compounds after 7 days of 
incubation. In all three cell lines, with the exception of the insulin-stimulated cell growth in 
the PANC-1 cell line, both 100 and 1000 IU/ml of IFN-β were capable of reducing the growth 
factor stimulated cell proliferation significantly. In addition to the dose-dependent effect of 
IFN-β there was also a time-dependent effect on basal proliferation as well as growth factor 
stimulated proliferation (data available on request).
3.5  inhibition of growth factor stimulated migration by ifn-β
We also evaluated whether INF-β was able to inhibit growth factor stimulated migration. 
Given that only in the BxPC-3 cell line there was a significant increase of growth factor 
stimulated migration, the effect of IFN-β on growth factor induced migration was assessed 
only in this cell line. Figure 5 shows the effects of 100 and 1000 IU/ml IFN-β on basal and 
growth factor stimulated cell migration after 8 hours of incubation. Similar to the experi-
ments described in figure 3b, at a concentration of 10nM, all growth factors stimulated the 
cell migration in a statistically significant manner (p<0.001). Furthermore, there was a 
significant inhibition of basal cell migration by 1000 IU/ml IFN-β (p<0.001). Both 100 and 
1000 IU/ml IFN-β were able to reduce IGF1 (p<0.01 and p<0.001, respectively) and IGF2 
(p<0.05 and p<0.001, respectively) stimulated cell migration significantly. Regarding the 
insulin stimulated cell migration, only the higher concentration of 1000 IU/ml IFN-β was 
capable of reducing the cell migration significantly (p<0.01).
4. discussion
Pancreatic cancer is a highly invasive malignancy with the potency to metastasize early. The 
highly aggressive nature of this disease can be explained by the overexpression of several 
factors, including insulin and insulin-like growth factors3,4. Previous research has shown that 
the IGF1R is overexpressed in substantial part of pancreatic cancer specimens and associ-
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figure 4: Effects of IFN-β treatment on cell proliferation after 7 days of incubation with and without the 
growth factors IGF1, IGF2 and insulin. The cells were incubated for 7 days with 100 IU/ml IFN-β, 1000 IU/
ml IFN-β or 10nM IGF1, IGF2 or insulin alone, or with the combination of 100IU/ml or 1000 IU/ml IFN-β 
and 10nM of IGF1 IGF2 or insulin. Values are expressed as the percentage of control and represent the 
mean ± SEM of at least 2 independent experiments in quadruplicate * p<0.05, ** p<0.01 and ***p<0.001 
versus control.
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ated with invasive and more proliferating tumors5. Besides that, it becomes more clearer 
that high levels of insulin can stimulate tumor growth. Moreover, several epidemiological 
studies associated diabetes mellitus, with the accompanying hyperinsulinism, and the use 
of insulin with an increased risk of certain cancers, as well as all-cause mortality12-14,23. Ad-
ditionally, given that insulin and IGFs may interact with each other’s receptors, the role of 
insulin and the insulin receptor should not be neglected. Nevertheless, to the best of our 
knowledge, there are no studies yet comparing the effects of IGF1, IGF2 and insulin on both 
cell proliferation and migration of pancreatic cancer cells.
In the present study we first evaluated the mRNA expression of the growth factors and 
their receptors. Among the 3 human pancreatic adenocarcinoma cell lines, there was a 
considerable variability in expression of the IGF1R, IRA and IRB receptors. None of the cell 
lines expressed detectable levels of IGF1 mRNA and only the PANC-1 and Hs 766T cell lines 
expressed IGF2 mRNA.
Overall, the cell proliferative effects of IGF1, -2 and insulin were time- and dose de-
pendent. However, in the Hs 766T cell line these effects compared to the other two cell 
lines, were much less pronounced, which might be explained by several reasons. First, in 
contrast to the other cell lines, IGF1R mRNA and protein expression is relatively low. Sec-
ondly, the IGF2 mRNA expression of this cell line is fairly high which can cause the IGF1 and 
insulin receptors to be already partially saturated. The addition of IGF1, IGF2 and insulin 
figure 5: Percentage of cell migration after 8 hours of incubation with 100 IU/ml IFN-β, 1000 IU/ml IFN-β 
or 10nM of IGF1,-2 or insulin alone, or with the combination of 100IU/ml or 1000 IU/ml IFN-β and 10nM 
of IGF1,-2 or insulin in the BxPC-3 cell line. Values are expressed as the percentage of wound closure 
compared to 0 time and represent the mean ± SEM of at least 3 independent experiments in triplicate, 
* p<0.05, ** p<0.01 and ***p<0.001 versus control.
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will, therefore, be minimally effective. Finally, the role of the family of IGF binding proteins 
(IGF-BPs) should not be ignored as they are capable of binding free circulating IGFs and 
thereby opposing the cell proliferating effects of IGFs. It has been described that in certain 
circumstances, like after serum starvation, IGF-BPs are also capable of stimulating cell 
growth24. Furthermore, IGF-BP3 and -5 are frequently overexpressed in pancreatic cancer 
and correlated with pancreatic cancer cell growth and a poorer survival.4,25-27 However, in 
the present study the role of IGFBP’s was not evaluated.
In healthy subjects with normal insulin sensitivity, after food intake peripheral insulin 
concentrations rise to approximately 0.5 to 1.0 nM. It is estimated that peri-acinar concen-
trations of insulin are at least 20-fold higher than in the peripheral circulation, and should 
peak at 10-20 nM23. Although more than 95% of circulating IGFs are bound, in total circulat-
ing concentrations of IGFs are much higher than the concentrations of insulin. Generally, 
the normal IGF concentrations in adulthood can vary between 4nM and 70nM. However, 
this range strongly depends on factors like age, gender, diet and the used technique to 
determine the concentration. Besides that there is a large biological variation between 
individuals which makes it difficult to determine a generally applicable reference range. 
Therefore, given this wide spread in physiological concentrations, regarding the different 
growth factors, a fixed concentration of 10nM was used to determine the IGF1, IGF2 and in-
sulin stimulated migration, as well as the potential inhibitory effects of IFN-β on the growth 
factor stimulated proliferation and migration. However, at this concentration the growth 
factors are capable of binding each other receptors and therefore it is not possible to 
fully correlate the effects of the growth factors with their receptors. Nevertheless, this data 
does imply that, regardless of receptor type or level of expression, an IGF1-, IGF2- and/or 
Insulin-stimulated effect can be exerted. Besides that, cancer cells themselves are capable 
of producing growth factors, thereby creating an environment with elevated concentra-
tions of the growth factors enabling themselves to proliferate and migrate4,25.
With the scratch assay method in vitro cell migration was evaluated. This method allows 
to study cell migration in vitro, which enables cell-cell interaction and to some extent mim-
ics cell migration in vivo. Although the scratch assay method is a validated method to study 
cell migration we validated this method with the Cytoselect ™Wound Healing assay, since 
in the scratch assay results can be compromised by the release of factors from damaged 
cells. However, we did not observe any differences between the two methods. As such, the 
scratch assay was a suitable method to study cell migration. Furthermore, by analyzing the 
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growth factor stimulated migration 8 hours after scratch we excluded the possibility of the 
involvement of cell proliferation.
Only in the BxPC-3 cell line a significant increase in cell migration was observed after 
stimulation with the different growth factors. No significant increased cell migration was 
observed in the PANC-1 and Hs 766T cell line. Considering the relatively low IGF1R expres-
sion and the less pronounced effects of the growth factors on cell proliferation after 3 and 
7 days in the Hs 766T cell line, the absence of stimulated cell migration after 8 hours could 
therefore be argued. Nevertheless, the absence of cell migration in the PANC-1 cell line is 
unexpected. It is known that cancer cell proliferation and migration are processes medi-
ated by several molecules in different signaling cascades. AKT and its upstream regulator 
p13K are primarily involved in malignant cell proliferation, whereas ERK and the Ras/RAF/
MAP kinase signaling pathways are more broadly involved in cellular functions like survival, 
proliferation, apoptosis and cell motility3,28,29. The epithelial-mesenchymal transition (EMT) 
is one of the initiators of the metastatic cascade and proteins involved in this EMT (e.g. 
Notch-2, Snail, N-Cadherin, Zeb, Vimentin and Slug) are also frequently overexpressed in 
pancreatic cancer30-32. As nicely investigated and described by Subramani et al., silencing 
the IGF1R resulted in an inhibition of proteins favoring pancreatic cancer EMT, additionally 
silencing of the receptor resulted as well in a downregulation of the active forms of AKT, 
P13K and mTOR by the upregulation of the tumor suppressor gene PTEN. Furthermore, by 
silencing of the receptor an effective inhibition of the active form of ERK was found. The au-
thors concluded that the reduced capacity of the pancreatic cancer cells to proliferate and 
migrate was due to the suppression of key molecular pathways affected by the knockdown 
of the IGF1R. However, these effects became apparent after silencing the receptor for at 
least 48hours. Additionally, the reduction in cell migration became statistically significant 
72 hours after the scratch. Therefore, it can be hypothesized, that with respect to this cell 
line, 8 hours of incubation with the different growth factors may not have been sufficiently 
long enough to detect enhanced cancer cell migration.
As demonstrated in previous research, INF-β is a very potent molecule in inhibiting 
cell proliferation and in inducing apoptosis in pancreatic cancer cells18,33. In addition, it is 
demonstrated that IFN-β is capable of modulating the IGF system by downregulating the 
expression of IGF1R and IGF2 mRNA in neuro-endocrine tumor cells16. However, despite 
these potent effects, there are no studies yet that evaluated the effects of IFN-β with respect 
to the IGF and insulin system in human pancreatic cancer cells. Therefore, in addition to the 
effects of insulin and insulin-like growth factors on pancreatic cancer cell proliferation and 
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migration we investigated the inhibitory effects of IFN-β on the growth factor stimulated 
proliferation and migration as well. As shown in previous research, and reaffirmed in this 
study, IFN-β is a potent inhibitor of pancreatic cancer cell growth. Moreover, after 3 days of 
incubation with the different growth factors, 100 IU/ml of IFN-β was capable of inhibiting 
IGF1-, IGF2- and insulin-stimulated proliferation in two out of three cell lines, whereas a 
1000 IU/ml of IFN-β was capable of inhibiting each growth factor stimulated proliferation 
in all three cell lines. These effects became even stronger after 7 days of incubation with 
both concentrations of IFN-β and the different growth factors. Besides the effect of IFN-β 
on growth factor stimulated proliferation we also studied the effect of IFN-β on growth 
factor stimulated migration. Since no significant effect of the growth factors was observed 
in the Hs 766T and PANC-1 cell line, we only evaluated the effect of IFN-β in the BxPC-3 cell 
line. In this cell line after 8 hours of incubation IFN-β (1000 IU/ml) significantly reduced 
basal migration as well as the migration stimulated by either IGF1, IGF2 or insulin. Addition-
ally, 100 IU/ml of IFN-β inhibited both the IGF1, as well as the IGF2, stimulated migration 
significantly, which can be due to the fact that IFN-β is capable of down regulating the 
IGF1R16. Nevertheless, the inhibitory effects of IFN-β on cell migration are less pronounced 
as compared to the effects on cell proliferation, indicating that the associated signaling 
pathways are predominately involved in cell proliferation rather than in cell migration34.
As clearly demonstrated in this study, insulin as well is capable of inducing cancer cell 
proliferation and migration. Besides that, it is known that IGFs and insulin can interact 
with each other receptors. Therefore, one can argue that targeting only the IGF1R will be 
insufficient in cancer treatment. Recently a new drug, OSI-906, has been developed that 
selectively inhibits autophosphorylation of both IGF1R and IR. OSI-906 hinders activation 
of downstream pathways and thereby inhibits migration, proliferation and survival in a 
variety of tumor cell lines35-37. Currently, OSI-906 is tested in advanced clinical studies. In 
future research, it would be interesting to test whether the anti-cancer effects of OSI-906 
and IFN-β reinforce each other.
In conclusion, this study is the first that demonstrates the potent stimulatory effects of 
IGF1, -2 and insulin with respect to pancreatic cancer cell proliferation and migration. These 
results are in line with the highly aggressive nature of this disease and confirm the potential 
malignant potencies of insulin. In addition, we showed that IFN-β potently inhibits IGF1, IGF2 
or insulin stimulated tumor cell growth, as well as the migration stimulated by these growth 
factors. In addition to the potent anti-tumor effects of IFN-β, these results therefore further 
favor the use of INF-β as part of the treatment options for patients with pancreatic cancer.
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abstract
background: Pancreatic cancer is the fourth leading cause of cancer related death in the 
Western world. Although multiple treatment strategies have been attempted, survival has 
barely been improved in the last 30 years. Recently, potent anti-tumor effects of interferon-β 
(IFN-β) have been demonstrated in vitro. However, the effect of IFN-β alone and in combina-
tion with a chemotherapeutic agent on the growth of pancreatic cancer in vivo is unknown. 
Additionally, there are no methods available yet to predict the effects of therapy before 
start of the treatment. In the present study we evaluated the effect of IFN-β mono- and 
combination therapy with gemcitabine in vitro, in vivo and ex vivo.
methods: The anti-tumor effects of IFN-β alone and combined with a suboptimal concen-
tration of gemcitabine were evaluated in an in vitro cell proliferation assay, in a heterotopic 
subcutaneous mouse model and in an ex vivo precision cut tissue slice model. For all experi-
ments the human pancreatic cancer cell line BxPC-3 was used.
results: in vitro: IFN-β pre-treatment significantly enhanced sensitivity of BxPC-3 cells to the 
inhibitory effect of gemcitabine. In vivo: After 30-days of treatment with the combination 
of IFN-β and gemcitabine, there was a significant reduction by 55% of tumor volume (com-
pared to vehicle treated animals). Both compounds tested alone, at the dosage used, did 
not significantly influence tumor growth. Additionally, tumors of mice treated with the drug 
combination showed a significant reduction in the number of proliferating cells, whereas 
there was a clear trend towards an increased apoptosis (Caspase-3 cleavage). Again, no 
statistically significant differences were found in tumors of mice treated with IFN-β or gem-
citabine monotherapy. Ex vivo: In tissue slices, combined IFN-β and gemcitabine treatment 
resulted in a visible loss of tissue integrity.
conclusion: While, at the dose tested, no effect of IFN-β alone on cancer growth in vivo was 
observed, this study demonstrates for the first time a potent chemosensitizing effects of 
INF-β when combined with gemcitabine in vitro, in vivo and ex vivo, already at suboptimal 
concentrations of gemcitabine. Therefore, the use of IFN-β as adjuvant treatment of pancre-
atic cancer seems promising and needs to be further explored.
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1.  introduction
Patients diagnosed with pancreatic cancer have one of the most dismal prognoses. The 
overall 5-year survival rate is less than 6%, with a median survival of 4-6 months. The 
treatment of choice is surgery followed by adjuvant chemotherapy. However, at time of 
diagnosis the majority of patients present with locally advanced or metastatic disease and 
chemotherapeutic response rates are often disappointing1,2. Although multiple chemora-
diation treatment strategies have been attempted, over the last 30 years pancreatic cancer 
mortality rates have barely been improved. Over the past decade research has focused on 
other treatment strategies, including biological response modifiers such as interferons 
(IFNs).
Type I interferons (i.e. IFN-α and –β) are cytokines that have a wide range of potential 
anti-cancer effects. They are capable of inhibiting cell proliferation, inducing apoptosis, 
block cell cycle and, importantly, are able to sensitize tumor cells for chemo- and radio-
therapy.
A few years ago several clinical studies3-7 demonstrated promising results indicating 
that there might be a role for adjuvant IFN-α therapy. Nevertheless, in all studies the major-
ity of patients experienced grade 3 or 4 treatment toxicities and, therefore, the use of IFN-α 
in the treatment of pancreatic cancer remains controversial.
Recently, several in vitro studies showed promising results regarding IFN-β therapy. First, 
the study of Vitale et al.8 demonstrated in human pancreatic cancer cells that IFN-β induces 
a more potent and early apoptosis and cell cycle arrest compared to IFN-α. Furthermore, 
other research groups demonstrated strong chemo- and radiosensitizing effects of IFN-β, 
even in cell lines that are non-responsive to IFN-α9-11. Furthermore, a study by our research 
group evaluated the effects of IFN-α and –β in eleven human pancreatic cancer cell lines 
and demonstrated that IFN-β is able to induce already at low concentrations very potent 
anti-tumor effects, an effect being less dependent on IFN receptor expression12. In addi-
tion, it has been described that IFN-β has a higher binding affinity for the receptor complex 
compared to IFN-α13, which is of significance since only a small proportion of the pancreatic 
cancer patients have a high expression of the binding subunit of the type I interferon recep-
tor14. More recently, our research group demonstrated that IFN-β is capable of inhibiting 
Insulin-like Growth Factor (IGF)- and insulin-stimulated pancreatic cancer cell proliferation 
and migration (Booy et al. American Journal of Cancer Research, provisionally accepted). 
However, surprisingly there are no in vivo and/or clinical studies that investigated the use of 
concomitant adjuvant IFN-β therapy in the treatment of pancreatic cancer15.
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In the present study we therefore evaluated the effect of IFN-β alone and in combination 
with gemcitabine in a heterotopic pancreatic cancer mouse model. Additionally, in order to 
try to predict the effects ex vivo, we evaluated the effects of IFN-β mono- and combination 
therapy in a pancreatic cancer xenograft tissue slice model.
2.  materials and methods
2.1  cell lines and culture conditions
The human pancreatic cancer cell line BxPC-3 was obtained from the American Type Culture 
Collection (Rockville, MD, USA). Before use the cell line was allelotyped and the DNA (STR) 
profile corresponded with the profile of the ATCC. The cells were cultured in a humidified 
incubator at 5% CO2 and 37°C. The culture medium consisted of RPMI 1640 supplemented 
with 5% FCS, penicillin (1x105 U/L) and L-glutamine (2 mmol/l). Cells were confirmed as 
mycoplasma-free. Cells were harvested with trypsin (0.05%)-EDTA (0.53 mM) solution. 
Before plating or injection, cells were counted microscopically using a standard haemocy-
tometer. Trypan blue staining was used to determine cell viability. Media and supplements 
were obtained from GIBCO Bio-cult Europe (Invitrogen, Breda, The Netherlands).
2.2  drugs and reagents
Human recombinant IFN-β-1a was acquired from Serono Inc. (Rebif, Rockland, MA, USA) 
kept at 4ºC and diluted in 0.9% NaCl at time of use. Gemcitabine Actavis (Actavis Group PTC, 
Hafnarfjordur, Iceland) was kept at room temperature and made fresh in 0.9% NaCl at the 
day of use.
2.3  cell proliferation assay
After trypsinization, the cells were plated in 1 ml of medium in 24-well plates at the correct 
cell density. The plates were placed in a 37ºC, 5% CO2 incubator and cells were allowed to 
attach overnight. The next day, cells were pre-incubated for 24 hours with 1000 IU/ml of 
IFN-β. Hereafter, the medium was refreshed and incubated for another 24 hours, or for the 
remaining time of the experiment (3-days), with increasing concentrations (0.05- 5.0 ng/ml) 
of gemcitabine. Each treatment was performed in quadruplicate. After 3 days of treatment, 
the cells were harvested for DNA measurement. The measurement of total DNA contents, 
as previously described, was performed using the bisbenzimide fluorescent dye (Hoechst 
33258) (Boehring Diagnostics, La Jolla, CA)16.
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2.4  animals and heterotopic injection of tumor cells.
Male athymic Balb/C nude mice (Harlan laboratories, UK ltd) of eight weeks old were used 
in this study. The animals were kept in a barrier facility under HEPA filtration. Mice were 
maintained on a daily 12-h light/12-h dark cycle in cages with autoclaved bedding, water 
and autoclaved laboratory rodent diet were given ad libitum.
For tumor cell injection, cells were harvested from culture flasks, as described earlier, 
and dissolved in phosphate buffered saline (PBS). Only single-cell suspensions of greater 
than 90% viability were used for injection. Tumor cells (1x106/100µl PBS) were subcutane-
ously injected at the flank of each mouse after which the mice were randomly divided into 
four groups (n=8 each). A separate group of five mice, which did not receive any treatment, 
were used for the tissue slice experiments. All animal studies were done in accordance to 
protocols approved by the committee on animal research of the Erasmus Medical Center, 
Rotterdam, the Netherlands.
2.5  therapy and assessment of tumor size
Tumor size and body weight was measured twice weekly. Tumor volume were evaluated as 
(length x width)1.5x (π/6). When the tumor volume reached ~150mm3 treatment was started. 
Mice in the control group received five times a week, on consecutive days, an intraperito-
neal (i.p.) injection of 100µl of 0.9% NaCL. Mice in the IFN-β monotherapy group received 
upon start of the treatment, 5 times a week, on consecutive days, an injection of 1.5x105 
IU of IFN-β intraperitonealy. Mice randomized to the gemcitabine monotherapy group 
received two times a week an i.p. injection of 40mg/kg gemcitabine. Mice in the IFN-β and 
gemcitabine combination group received upon start of the treatment, 5 times a week, on 
consecutive days, an injection of 1.5x105 IU of IFN-β intraperitonealy and, on day 2 and 4, an 
i.p. injection of 40mg/kg gemcitabine.
2.6  necropsy procedures
Mice, under isoflurane anaesthesia, were sacrificed by cervical dislocation after 4 weeks of 
treatment, or when tumor volume reached 2000mm3 (1500mm3 for tumors of mice used 
in the tissue slice experiments) or when the wellbeing (i.e. weight loss, lethargy, tumor 
ulceration) of the mice could no longer be maintained.
During necropsy, tumors were resected and tumor weight and volume were measured. 
Tumors were divided into three parts and subsequently snap frozen in liquid nitrogen, 
embedded in Tissue-Tek (Sakura Finetek, Zoeterwoude, the Netherlands) for cryosectioning 
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and fixed in freshly prepared 4% formaldehyde solution, and prepared for paraffin section-
ing. Furthermore, mice organs (pancreas, liver, lungs, brain, heart, spleen and kidneys) were 
harvested, weighted and fixed in 4% formaldehyde.
2.7  tissue slicing and slice culture
When tumors reached a volume of 1500 mm3, mice were sacrificed and necropsy was per-
formed as described above, however, tumors were not divided for histology. After resection, 
tumors were washed twice with Hanks’ Balanced Salt Solution (HBSS) supplemented with 
penicillin (1x105 U/L), streptomycin(1000 IU/ml) and fungizone (30µg/ml).
After the vibrocheck (measurement of vertical deflection) was performed, tumor speci-
mens, buffered in ice-cold HBSS, were cut, with stainless steel razor blades, into slices of 
200µm using the Leica vibrating blade microtome VT1000 S (Leica, Wetzlar, Germany). After 
slicing, samples were washed once more and transferred into six-well multiplates contain-
ing 5ml of culture medium consisting of Dulbecco’s Modified Eagle’s Medium: nutrient 
mixture F-12 (DMEM/F-12), supplemented with penicillin(1x105 U/L), streptomycin (1000IU/
ml) and 10% FCS. Consecutive slices were used for the experiments (minimum of 15 slices 
per tumor).
Tissue culture plates were placed in a humidified incubator at 5% CO2 and continuously 
shaken (60 rounds/min) at 37°C up to 4 days post slicing. Media and supplements were 
obtained from GIBCO Bio-cult Europe (Invitrogen, Breda, The Netherlands).
After 24 hours, media were refreshed and slices were incubated with IFN-β (1000 IU/
ml), gemcitabine (1ng/ml), or with the combination of IFN-β and gemcitabine. At baseline 
and after 72 hours of incubation tissue slices were harvested fixed in freshly prepared 4% 
formaldehyde solution and prepared (in upright position) for standard paraffin sectioning.
2.8  immunohistochemistry
The formalin fixed and paraffin embedded sections (5µm thick) were treated for im-
munohistochemistry as described previously14. Briefly, sections were deparaffinised and 
rehydrated, followed by heat induced epitope retrieval (HIER), rinsed (TRIS/Tween 0.5% (pH 
8.0)) and blocked (hydrogen peroxide 3% in PBS) for 15 minutes before incubation with the 
primary antibodies for Caspase-3 and Ki-67 (both overnight at 4° C). For negative controls, 
the primary antibody was omitted. The Dako Real EnVision Detection System kit (Dako 
Detection System, Dako Denmark, Glostrup, Denmark) was used to visualize the bound 
antibody after which the slides were counterstained with haematoxylin and coverslipped. 
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The rabbit monoclonal Cleaved Caspase-3 (Asp175) antibody (cell signalling technology, 
Beverly, MA, USA) was used at a dilution of 1:750. The mouse monoclonal Ki-67 antibody 
(Dako Detection System) was used at a dilution of 1:400.
2.9  immunohistochemical analysis
All sections were evaluated and counted independently by two investigators (SB and LJH). 
Apoptosis was assessed by counting the total number of caspase-3 positive tumor cells per 
high-power field (HPF x40 objective). Cell proliferation was assessed by the evaluation of 
Ki-67 positive tumor cells per HPF (HPF x40 objective). For the analysis a minimum of 3 HPF 
were used to evaluate cells with a positive and negative staining.
2.10  statistical analysis
For statistical analysis GraphPad Prism 5.0 (GraphPad software, San Diego, CA) was used. All 
in vitro experiments were carried out at least thrice. The comparative statistical evaluation 
among groups was performed by a one-way ANOVA test. When significant differences were 
found, a comparison between groups was made using the Newman-Keuls test. Regarding 
the in vivo experiments the difference between groups were evaluated by the Mann-Whit-
ney t-test. In all analyses, values of p<0.05 were considered statistically significant. Data are 
reported as mean ±SEM.
3.  results
3.1  effects of ifn-β mono- and combination therapy in vitro
Before gemcitabine treatment pancreatic cancer cells were pre-incubated with IFN-β. There-
after, cells were incubated with increasing concentrations of gemcitabine for 24-hours. The 
effects of gemcitabine treatment alone on the inhibition of cell proliferation were dose-
dependent. After 24-hours of gemcitabine treatment, pre-incubation of pancreatic cancer 
cells with IFN-β resulted, already at low concentrations of gemcitabine (up to 0.05 ng/ml), 
in a statistically significant more potent inhibition of cell proliferation, compared to cells 
treated with gemcitabine alone (inhibition of cell proliferation by concentrations ≥ 0.5 ng/
ml). Data are shown in Figure 1.
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3.2  effects of ifn-β mono- and combination therapy in vivo
The effects of IFN-β therapy, alone, or in combination with gemcitabine, were investi-
gated in a heterotopic subcutaneous pancreatic carcinoma mouse model. Treatments 
with gemcitabine or IFN-β alone, or in combination with gemcitabine, were well toler-
ated as determined by maintenance of body weight. After 4 weeks of treatment no sig-
nificant differences were found in body weight between the treatment groups (Table  1). 
figure 1. Effects of treatment with gemcitabine alone (grey bars) or after 24 hours of pre-incubation 
with IFN-β (white bars) on human pancreatic cancer cell line BxPC-3 cell proliferation. The cells were 
pre-incubated without or with 1000 IU/ml of IFN-β and subsequently with increasing concentrations of 
gemcitabine during 24 hours (upper figure) or 72 hours (lower figure). After 3 days of treatment cells 
were harvest for DNA measurement. Values are expressed as the percentage of control and represent 
the mean ± SEM of at least 2 independent experiments in quadruplicate. **p<0.01 and ***p<0.001 versus 
gemcitabine alone treatment.
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However, in the group of mice treated with gemcitabine, one mice was found dead before 
start of the treatment and one mice at the end of the total treatment cycle. Due to organ 
and tumor lysis necropsy was not possible anymore.
The time course of the growth of tumor volume is depicted in figure 2a. Compared to 
the control, after 4 weeks of treatment with IFN-β and gemcitabine, a significant reduction 
table 1. Treatment of subcutaneous heterotopic human pancreatic tumors in nude mice.
treatment groups
completion tumor volume (mm3) tumor weight (g) body weight (g)
of treatment Median Range Median Range Median Range
Control 5/8a 798 524-902 576 373-790 28 25-30
IFN-β 7/8a 497 227-1179 468 161-852 27 25-29
gemcitabine  5/7a+b 518 210-1225 780 248-1121 25 25-30
IFN-β + gemcitabine 6/8a 293c 147-641 418 161-559 27 25-27
a Number of mice that completed 4 weeks of treatment. Mice were sacrificed before the end of treatment 
if the wellbeing of the animal could not be maintained (in all these mice this was due to ulceration of the 
tumor).
b One mice died before the start of the treatment.
c P < 0.05 versus control
figure 2: 2a: Time course change in estimated tumor volume of the subcutaneous injected BxPC-3 tumor 
cells in nude mice. Mice received intraperitoneal injections of 0.9% NaCL (closed circles), 1,5x105 IU of 
IFN-β (closed triangle), 40mg/kg gemcitabine (open squares) or the combination of 1,5x105 IU of IFN-β 
and 40mg/kg gemcitabine (open circles). Figures represent the mean. * p<0.05 versus control. 2b: After 4 
weeks of treatment mice were sacrificed and tumor volume was measured. Figures represent the mean ± 
SEM. * p<0.05 versus control.
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of tumor volume by 55% was found (Table 1 and Figure 2b). No statistically significant dif-
ferences were found regarding tumor weight.
All tumors expressed Ki-67 and cleaved caspase-3. Compared to the control, no differ-
ences were found in Ki-67 and cleaved caspase-3 expression in the tumors of mice treated 
with IFN-β and gemcitabine alone. In tumors of mice treated with IFN-β and gemcitabine 
alone, and in combination, there was a statistically significant reduction in the proportion of 
proliferation, Ki-67 positive cells (Figure 3, left panel; p<0.01). Additionally, a trend towards 
an increased apoptosis was found, which was most evident in the tumors of mice treated 
with the combination of both drugs (Figure 3, right panel).
3.3  effects of ifn-β mono- and combination therapy ex vivo
In order to attempt to use a model that might predict the effects of the treatment with 
IFN-β, gemcitabine and the combination in vivo, an ex vivo precision cut tissue slice model 
was used.
figure 3. Immunohistochemical analysis of cleaved caspase-3 and Ki-67 expression in the subcutaneous 
human pancreatic tumors in nude mice that developed after the injection of BxPC-3 tumor cells. The left 
figure shows the percentage of Ki-67 positive cells, representing the proportion of proliferating cells, the 
right figure shows the percentage of positive cells expressing cleaved caspase-3, representing the pro-
portion of apoptotic cells, in the different treatment groups. Values are expressed as the percentage of 
total cells and represents the mean ± SEM of at least 3 different areas within the tumor and the score of 
two independent investigators. * p< 0.05 and **p<0.01 versus control.
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Four xenograft tumors of untreated mice were used to create the tissue slices. Slices 
were incubated for 72-hours with IFN-β, gemcitabine and the combination of gemcitabine 
and IFN-β. After 72 hours of culture, small foci of necrosis were observed in all slices, how-
ever, in the slices treated with the combination of gemcitabine and IFN-β a clear increased 
loss of tissue structure and a decrease of the amount of viable cells was observed (Figure 4).
4.  discussion
With an estimation of 165.100 new cases and 161.800 estimated deaths, pancreatic cancer 
is the fourth leading cause of cancer related death in the Western world. Despite multiple 
different chemo- and radiotherapeutic treatment strategies that have been attempted, the 
outcome of patients with pancreatic cancer remains poor with a total overall survival of less 
than 6%1,2. Although promising results have been reported regarding IFN-α therapy in the 
adjuvant treatment of pancreatic cancer, the use of IFN-α is disputable as treatment toxici-
ties were notably high and the only randomized study so far did not show any significant 
figure 4. Haematoxylin & eosin staining of representative tissue slides of human pancreatic cancer xe-
nograft tissue slices (mice 1-4) collected at baseline, and after 72 hours of incubation with 0.9% NaCL 
(vehicle), 1000 IU/ml INF-β, 1 ng/ml gemcitabine, or the combination of IFN-β and gemcitabine. Original 
magnification x200.
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differences between treatment groups3-7. Nevertheless, several studies, including a study by 
our research group, demonstrated potent anti-cancer effects, already at low concentrations 
of IFN-β, and it has been described that IFN-β has a higher binding affinity for the receptor 
complex compared to IFN-α8-13. In this respect, adjuvant IFN-β therapy might be promising. 
As such, the main aim of the present study was to evaluate the effect of IFN-β, alone and 
in combination with the chemotherapeutic agent gemcitabine in a heterotopic pancreatic 
cancer mouse model.
Based on the response to type I IFNs and the amount of IFN receptors expressed we 
choose to use the human pancreatic cancer cell line BxPC-312. First, we evaluated the effect 
of IFN-β in combination with gemcitabine in vitro and demonstrated a potent chemosen-
sitizing effects of IFN-β. Already after 24 hours of pre-incubation with IFN-β the synergistic 
cell growth inhibitory effects of combined gemcitabine treatment became apparent. Such 
synergistic anti-tumor effects of IFN-β and gemcitabine, even in pancreatic cancer cells with 
low IFN receptor expression, were demonstrated as well in a more comprehensive study by 
Tomimaru et al., 11. However, the in vivo effects of IFN-β combined with gemcitabine were 
not investigated in this study.
By using a heterotopic subcutaneous pancreatic cancer mouse model the effects of IFN-β, 
alone and combined with gemcitabine, were determined. Regarding in vivo research, the 
most frequently used concentration of gemcitabine varies between 100 mg/kg and 125 mg/
kg17,18. Nevertheless, based on the previously described in vitro findings we decided to reduce 
the concentration of gemcitabine and used a suboptimal concentration of 40 mg/kg.
As expected, given this suboptimal treatment dose, no statistically significant decrease 
of tumor volume or weight was found in tumors of mice treated with gemcitabine alone. 
Additionally, despite the potent anti-tumor effects in vitro, no difference was found in the 
tumors of mice treated with IFN-β alone, however, there was a clear trend towards a smaller 
tumor volume. Although IFN-β concentrations were not measured in this study, it may be 
possible that the circulating concentration of IFN-β was not sufficient. This may be related 
to the relatively short half-life of IFNs in the circulation19,20. In vitro, the concentration of 
IFN-β required to reduce cell growth to 50% in a large series of pancreatic cancer cell lines 
ranged between 70-1000 IU/ml12. Regarding the BxPC-3 cell line, the concentration required 
to reduce cell growth with 50% in vitro was 114 IU/ml. These concentrations are not easily 
reached (4-0 IU/ml after four doses of 18 MIU IFN-β at 48-h intervals in serum of human 
healthy volunteers after s.c. administration)19. Furthermore, the potent direct anti-tumor 
activities of type I IFNs can be limited by the activation of several survival pathways, like the 
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induction of the JAK2/STAT-3 pathway, the activation of nuclear factor kappa-beta (NF-κB) 
and the increased expression of the epidermal growth factor receptor (EGF-R). This could 
results in the stimulation of cell proliferation, malignant transformation and invasion and 
the inhibition of apoptosis21,22.
Gemcitabine is a cell-cycle specific inhibitor of DNA synthesis and is still the golden 
standard chemotherapeutic agent in the adjuvant treatment of pancreatic cancer23. Besides 
the induction of apoptosis and the inhibition of proliferation interferons are also able to 
induce a G0-G1 arrest, to prolong the S-phase transition and to block cells in G2/M and 
thereby sensitize tumor cells for chemo- and radiotherapy24,25. After 30 days of treatment, 
compared to the control, we observed a significant synergistic effect of the combined 
therapy of IFN-β and gemcitabine which was reflected in the reduction of tumor volume 
and, additionally, in a decreased proportion of proliferating tumor cells. Furthermore, a 
clear trend towards increased apoptosis (increased number of cleaved caspase-3 positive 
cells) was found in tumors of mice treated with gemcitabine and IFN-β.
Despite being the backbone in adjuvant pancreatic cancer treatment, response rates 
of gemcitabine are less than 20%23. Therefore it would be desirable to predict the response 
to IFN-β and gemcitabine therapy before start of the treatment and prevent unnecessary 
treatment toxicities. In this respect the ex vivo tissue slice model, already demonstrated by 
several other groups, seems very promising26-29. The advantage of this model is the ability to 
evaluate multiple treatments in one tumor sample. Furthermore, by the use of an automatic 
tissue slicer, comparable slices in size and viability can be obtained without tissue damage 
at baseline. In this study we were able to maintain viable slices up to 4 days of culture. This is 
in agreement with findings of two other studies who reported good cell viability at 72 hours 
even, independent of medium formulation, up to 6 days26,28. As nicely demonstrated by the 
HE-stained slides, a clear decrease in tissue structure was observed in the slices treated with 
the combination of gemcitabine and IFN-β. This was not observed in the vehicle treated 
slices, indicating that the loss of tissue structure is very likely an effect of the treatment. 
Despite the fact that these results seems promising, some major challenges (i.e. number 
and size of available tumors ,determination of compound concentration and validation of 
the effects) needs to be elaborated in the future before this technique can be used in the 
clinical setting. Nevertheless, for future pancreatic cancer research this technique seems 
promising.
Our study has its limitations as well. Firstly, the mouse model used was a heterotopic 
subcutaneous model. Although heterotopic models are often used in cancer research, it will 
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be important to evaluate the effects of IFN-β and gemcitabine in an orthotopic model as 
well. Especially since type I interferons are known to have immunoregulatory activities and 
interact with cells representing the host immune response. However, the role of IFN-β re-
garding cancer immunoediting could not be studied in the model of athymic mice or in the 
ex vivo tissue slice model. Currently, much research efforts are focused on the development 
of immunotherapeutic strategies30,31 and therefore it will be interesting to evaluate the 
immunomodulatory host effects of IFN-β combination therapy. As mentioned previously, 
a challenge of IFN therapy remains the relatively short half-life of IFNs in the circulation. 
However, advantage can be gained from PEGylated forms of IFN-α and –β, in which lower 
and less frequent doses are required, compared to the conventional IFNs. The PEGylated 
form of IFN-α has already proven to be effective in the treatment of grade III melanoma32 
and metastatic renal cell carcinoma patients33. Recently, a PEGylated form of IFN-β has been 
developed which, 20 hours after a single s.c. dose of 3.0 MIU/kg, resulted in monkeys in 
a serum concentration of 100 IU/ml. Currently this form of PEGylated IFN-β is tested in a 
phase III clinical trial (ADVANCE) in patients with multiple sclerosis34,35.
In conclusion, to the best of our knowledge, this is the first study that determined the ef-
fects of IFN-β alone and in combination with gemcitabine on human pancreatic cancer cells 
in three different experimental models. Although in vivo no statistically significant effects 
on tumor volume were found by IFN-β or gemcitabine monotherapy, a potent synergistic 
anti-tumor effect of the combination treatment with IFN-β and gemcitabine was observed 
in vitro, in vivo and ex vivo. These anti-tumor effects were already present at low concentra-
tions of gemcitabine. However, in order to demonstrate the potent anti-tumor activities 
of combined gemcitabine/IFN-β therapy in the clinical setting, prospective studies are 
necessary.
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abstract
objectives: Interferons (IFNs) have several anticancer mechanisms. A number of clinical tri-
als have been conducted regarding adjuvant IFN-alpha therapy in pancreatic cancer. Type-I 
IFNs exert their effect via the type-I IFN receptor (IFNAR-1, IFNAR-2c). The aim of the present 
study was to determine the type-I IFN receptor expression in pancreatic and periampullary 
cancer tissues and to study its relation with clinicopathological factors.
methods: Receptor expression was determined by immunohistochemistry in paraffin 
embedded cancer tissue of 47 pancreatic and 54 periampullary cancer patients.
results: 91.5% of the pancreatic and 88.9% of the periampullary tumors showed expres-
sion of IFNAR-1, of which 23.4% and 13.0% were strongly positive, respectively. Regarding 
IFNAR-2c expression, 68.1% of the pancreatic and 68.5% of the periampullary tumors were 
positive, of which 4.3% of the pancreatic and none of the periampullary tumors had a strong 
expression. No statistically significant associations were found between type-I IFN receptor 
expression and clinicopathological factors or survival.
conclusions: Type-I IFN receptors are expressed in pancreatic and periampullary cancer 
tissue although with great inter- and intratumoral variability. A small proportion of both 
tumors showed a strong expression of the IFNAR-1, only a very small percentage of the 
pancreatic tumors showed strong expression of the IFNAR-2c.
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1.  introduction
Pancreatic cancer, with 165.100 estimated new cases and 161.800 estimated deaths, is 
one of the most devastating malignant diseases in the western world1. It carries a dismal 
prognosis with an overall 5-year survival rate of less than 6%. Surgery is the only curative 
therapy but, due to locally advanced or metastatic disease, only 15-20% of the patients are 
eligible for resection at time of presentation. After successful surgery, prognosis remains 
poor mostly due to the aggressive local growth and rapid development of metastasis. Ad-
juvant therapy is necessary to improve survival but up till now chemo- and radiotherapy as 
additional treatments have proven to be of limited benefit2. Therefore research has focused 
on other treatment modalities, like adding biological modulators such as type I interferons.
Interferons (IFNs) are known to have anti-proliferative, antiviral and immunoregulatory 
activities. They are able to induce apoptosis and exert cell cycle blocking. Besides that they 
are able to sensitize tumor cells for chemo and radiotherapy3,4. Type I IFNs (e.g. IFN-α and 
IFN-β) act via the type I IFN receptor (IFNAR) complex of which IFNAR-1 and IFNAR-2c are 
the most important subunits5.
Although there was little in vitro knowledge on the mechanisms of action of interferons 
in pancreatic cancer, several clinical studies have been conducted regarding IFN-α as ad-
ditional adjuvant treatment. Investigators from the Virginia Mason Medical Center included 
43 patients to interferon based combination therapy (5-FU, cisplatin, interferon-α, and 
radiotherapy) and reported a tremendous increase in the 2 and 5-year survival (respectively 
64% and 55%) 6. Several other institutions, all single treatment-arm studies, hoped to con-
firm these encouraging data but only three of them reported similar findings. Besides that, 
in the majority of the patients grade 3+ toxicities were observed7-11. The only phase III trial 
evaluating this adjuvant regimen was the CapRI (Combined Chemoradioimmunotherapy 
for Pancreatic Adenocarcinoma) trial12. This study showed a longer median survival in the 
experimental arm, although this survival benefit was not statistically significant. This differ-
ence in median survival of 3,6 months implies that some patients probably benefited from 
the experimental treatment, even though 85% of these patients experienced grade 3 or 4 
toxicities.
In order to accomplish a direct effect of type I IFNs, the presence of the type I IFN 
receptor is necessary3,5. Surprisingly; in none of the patients treated with adjuvant IFN-α 
in clinical trials, the tumoral type I IFN receptor expression was known. Furthermore, no 
clear distinctions were made regarding cancer origin. Periampullary cancers, like distal bile 
duct and ampullary carcinomas, arise in the same anatomical area and are subjected to the 
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same surgical procedure as pancreatic cancers. Nevertheless, these cancers have different 
prognosis and therefore the distinction between pancreatic and periampullary cancers is 
of upmost importance 13,14. Knowledge of type I IFN receptor expression in pancreatic and 
periampullary cancer tissue is of great importance and may prevent unnecessary, often 
toxic, treatments in these cancer patients. Therefore, this study evaluated the type I IFN 
receptor expression in tissue of pancreatic as well as in tissue of periampullary cancer 
patients. Additionally, we determined whether the level of IFN receptor expression was 
associated with clinicopathological factors and outcome.
2.  Patients and methods
2.1  Patient population
Paraffin embedded cancer specimens of 168 patients with pancreatic or periampullary 
(ampullary or distal bile duct) cancer, who underwent intentional curative surgery in the 
Erasmus Medical Centre between the period of January 2000 and January 2007, were 
obtained, allowing a follow-up of at least five years. Pancreatic head specimens were care-
fully selected and revised by an experienced pathologist (KB). Tumor origin was based on 
the anatomical relationship of the center of the tumor mass, and presence of precursor 
lesions, to the ampulla, common bile duct or pancreas14. After revision cancer specimens 
of 20 patients were excluded due to indefinable tumor origin. A total of 72 pancreatic 
cancer patients and 76 periampullary cancer patients remained of which 25 tissue blocks of 
pancreatic cancer patients and 22 tissue blocks of periampullary cancer patients were not 
available for adequate analysis (Fig. S1 and Supplemental Legend, supporting information, 
at http://links.lww.com/MPA/A321).
In the period between January 2000 and January 2007, 31 patients of our series (14 
pancreatic cancer and 17 peri-ampullary cancer patients) were randomized to the treat-
ment arm of a trial combining adjuvant intra-arterial chemotherapy in combination with 
radiotherapy. Patients received 6 cycles of 5 treatment days, with an interval of 4 weeks 
between each cycle, of intra-arterial mitoxantrone (10mg/m2, day 1), folinic acid (170 mg/
m2 day 2 and 4), 5-fluorouracil (600mg/m2 day 2 and 4) and cisplatinum (60 mg/m2 day 
5). Two weeks after the first cycle of chemotherapy, 6 weeks of radiotherapy (total dose 
of 54 Gray (Gy) in single doses of 1.8Gy/day, 5 days a week) was started. The results and 
details of this trail have been described elsewhere15. Clinical and pathological information 
was derived from medical records. Tumors were staged according to the 7th edition of the 
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American Joint Committee Guidelines on cancer staging issued in 2009. Tumor histology 
was classified as well, moderately and poorly differentiated. At the time of the present 
report, the median follow-up duration of the pancreatic cancer patients was 13 months 
(ranging from 1 to 115 months), the median follow-up duration of the periampullary cancer 
patients was 21 months (ranging from 4 to 141 months). The study was approved by the 
medical ethical committee of the Erasmus Medical Center.
2.2  immunohistochemistry
Formalin fixed, paraffin embedded sections ( 5µm thick) were deparaffinized and rehy-
drated, followed by heat induced epitope retrieval (HIER) using the PT Link, pretreatment 
module for tissue specimens (Dako Denmark, Glostrup, Denmark), rinsed with TRIS/Tween 
0.5% (pH 8.0) and blocked for 15 minutes in hydrogen peroxide 3% (final concentration) in 
phosphate buffered saline (PBS). After blocking the sections were washed with TRIS/Tween 
0.5% and incubated with the primary antibodies for IFNAR-1 and IFNAR-2c (both overnight 
at 4° C). Negative control for the immunohistochemistry included omission of the primary 
antibody. To visualize the bound antibody a two-step procedure was conducted using the 
Dako Real EnVision Detection System kit (Dako Detection System, Dako Denmark, Glostrup, 
Denmark). Briefly, the sections were incubated for 30 minutes with three drops of horserad-
ish peroxidase rabbit/mouse and visualized with freshly prepared DAB+ Chromogen twice 
for 5 minutes in the dark. Slides were counterstained with hematoxylin and coverslipped. 
The mouse monoclonal anti-IFNAR-1 antibody (Sigma Aldrich, Saint Louis, MO, USA) was 
used at a dilution of 1:4800. The specificity of the IFNAR-1 antibody was demonstrated by 
western blotting (Fig. S2 and Supplemental Legend, supporting information, at http://links.
lww.com/MPA/A321). The anti-IFNAR-2c mouse monoclonal antibody (kindly provided by 
Dr. E. Croze, International review of investigational science, Lafayette, CA, USA) was used 
at a dilution of 1:800. The use and specificity of the IFNAR-2c antibody has been described 
previously3,16 and demonstrated by western blotting (Fig.  S2 and Supplemental Legend, 
supporting information, at http://links.lww.com/MPA/A321).
2.3  immunohistochemical analysis
Slides were examined and scored by a pathologist blinded to both clinical and pathological 
data. The semi-quantitative analysis of the stained slides in this study was done based on 
the Immunoreactivity score (IRS) described by Remmele and Stegner17 and according to the 
modification of McCarty et al18-20. Briefly, the IRS is calculated by the product of percentage 
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of positive cells (>80%: 4; 51-80%: 3; 10-50%: 2;  <10%: 1 and 0%: 0) and the intensity of 
the staining (strong: 3; moderate: 2; mild: 1 and no staining: 0). A score of 0-1(IRS 0) was 
considered as negative, 2-3 as weak positive (IRS 1), 4-8 moderate positive(IRS 2) and 9-12 
strongly positive (IRS 3) (Table  S1, supporting information, at http://links.lww.com/MPA/
A323).
2.4  statistical analysis
Data were analyzed using SPSS version 20.0 for windows. To evaluate differences in distribu-
tion of clinicopathological parameters and to determine the relationship between these pa-
rameters and the expression of the IFNAR-1 and IFNAR-2c, linear regression, the chi-square 
or fisher exact test, when appropriate, was used. Overall survival (OS) was defined as the 
number of months from resection to death of any cause. The probability of overall survival 
was calculated according to the Kaplan-Meier method and compared with the log-rank test. 
For univariate and multivariate analysis the Cox proportional hazard model was used. Only 
variables with a p-value of 0.10 or less on the univariate analysis were incorporated into the 
multivariate model. A p-value < 0.05 was considered statistically significant.
3.  results
3.1  Patient population
For analysis 47 pancreatic cancer paraffin embedded blocks and 54 periampullary cancer 
paraffin blocks (35 ampullary cancer and 19 distal bile duct cancer patients) were available 
(Fig S1, supporting information).
The mean age of patients with pancreatic cancer was 64 years, ranging from 33 to 79 
years. Regarding the periampullary cancer patients the mean age was 65 years, ranging 
from 39 to 81 years. Patient and tumor characteristics were similar among the pancreatic 
and periampullary cancer patients except for a significant difference in primary tumor stag-
ing (more T3 pancreatic cancer tumors and more T4 periampullary cancer tumors; p<0.001), 
a borderline significant difference in resection margins (more R1 resections in pancreatic 
cancer patients; p=0.05) and a surprisingly modest difference in observed perineural inva-
sion (more perineural invasion in periampullary cancer patients; p=0.05) (Table 1)
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table 1. Patients profiles
clinicopathological factors Pancreatic cancer
n=47( 46.5%)
Periampullary cancer
n=54 ( 53.5%)
p value
Age (range), yrs 64 (33-79) 65(39-81) 0.76
Gender 0.68
Male 27 (57.4) 34 (63.0)
Female 20 (42.6) 20 (37.0)
Adjuvant therapy 1.00
Yes 14 (29.8) 17 (31.5)
No 33 (70.2) 37 (68.5)
Type operation 0.16
Whipple 12 (25.5) 13 (24.1)
PPPD 32 (68.1) 41 (75.9)
Other 3 (6.4) 0 (0.0)
Location n.a.
Pancreatic head 44 (93.6)
Pancreatic body 1 (2.1)
Pancreatic tail 2 (4.3)
Ampulla 35 (64.8)
Distal bile duct 19 (35.2)
Diameter (cm) 2.63 2.35 0.15
Primary tumor (pT†) 0.001*
T1 1 (2.1) 4 (7.4)
T2 6 (12.8) 11 (20.4)
T3 38 (80.9) 25 (46.3)
T4 2 (4.3) 14 (25.9)
Grade 0.71
Well differentiated 2 (4.3) 4 (5.7)
Moderately differentiated 33 (70.2) 33 (68.6)
Poorly differentiated 12 (25.5) 16 (25.7)
Regional lymph nodes (pN†) 0.84
N0 17 (36.2) 4 (33.3)
N1 30 (63.8) 36 (66.7)
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table 1. Patients profiles (continued)
clinicopathological factors Pancreatic cancer
n=47( 46.5%)
Periampullary cancer
n=54 ( 53.5%)
p value
Resection margins 0.05
R0 33 (70.2) 47 (87.0)
R1 14 (29.8) 7 (13.0)
Stage† 0.50
0-I 3 (6.4) 6 (16.7)
II-III 44 (93.6) 30 (83.3)
Vascular invasion 0.31
Positive 11 (23.4) 8 (14.8)
Negative 36 (76.6) 46 (85.2)
Perineural invasion 0.05
Positive 32 (68.1) 26 (48.1)
Negative 15 (31.9) 28 (51.9)
IFNAR-1 expression 0.59
Negative 4 (8.5) 6 (11.1)
Positive, mild 12 (25.5) 14 (25.9)
Positive, moderate 20 (42.6) 27 (50.0)
Positive, strong 11 (23.4) 7 (13.0)
IFNAR-2c expression 0.19
Negative 15 (31.9) 17(31.5)
Positive, mild 12 (25.5) 22 (40.7)
Positive, moderate 18 (38.3) 15 (27.8)
Positive, strong 2 (4.3) 0 (0.0)
IFNAR-1 + IFNAR-2c 0.08
Negative 23 (48.9) 27 (50.0)
Positive, mild 9 (19.1) 19 (35.2)
Positive, moderate 14 (29.8) 8 (14.8)
Positive, strong 1 (2.1) 0 (0.0)
Cancer related death 0.12
Yes 33 (71.7) 37 (84.1)
No 5 (10.9) 3 (6.8)
Complications 4 (8.7) 2 (4.5)
Unknown 4 (8.7) 2 (4.5)
 † Based on American Joint committee on cancer. AJCC cancer staging manual. 7th Ed.
* P-values were calculated by linear regression, chi-square or fisher exact test
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3.2  interferon receptor expression
Both IFNAR-1 and IFNAR-2c were heterogeneously expressed within pancreatic and peri-
ampullary cancer tissue. For each receptor, both cytoplasmic and membrane staining was 
observed (Fig. 1a).
figure 1: Immunohistochemical analysis of IFNAR-1 and IFNAR-2c expression in pancreatic and periam-
pullary cancer tissue. 1a: Examples of tumors from pancreatic cancer patients with IRS0, IRS1, IRS2 or IRS3 
staining of IFNAR-1 and IFNAR-2c. The tumors show heterogeneous expression of the IFNAR-1 and IFNAR-
2c receptors. 1b: Distribution of IFNAR-1 (dark-grey bars) and IFNAR-2c (light-grey bars) immunopositivity 
in tumors of 47 pancreatic cancer patients (left) and 54 periampullary cancer patients (right).
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Regarding the IFNAR-1 expression, in the pancreatic cancer patients group 8.5% (4/47) 
of the tumors had no expression, 25.5% (12/47) had a weak expression, 42.6% (20/47) had a 
moderate expression and 23.4% (11/47) of the tumors had a strong expression. In the group 
of patients with periampullary cancer this was 11.1% (6/54), 25.9% (14/54), 50.0% (27/54) 
and 13.0% (7/54) respectively. The expression of the IFNAR-2c in tumors of pancreatic 
cancer patients was in 31.9% (15/47) negative, 25.5% (12/47) weak, 38.3% (18/47) moderate 
and in 4.3% (2/47) strong. In the group of patients with periampullary cancer this was 31.5% 
(17/54), 40.7% (22/54), 27.8% (15/54) and 0% (0/54), respectively (Fig.1b). No significant cor-
relation was observed between IFNAR-1 and IFNAR-2c expression. Additionally, it is notable 
that the immune cells, probably macrophages, surrounding the tumor had a very strong 
staining for both receptors, in particularly the IFNAR-2c receptor (Fig. 2). Only one tumor of 
a pancreatic cancer patient was found with a very strong IFNAR-1 and IFNAR-2c expression 
(IRS 3) (Fig.2).
figure 2: Representative case of pancreatic cancer tissue with high IFNAR-1 (panel B) and IFNAR-2c (panel 
C) staining (both IRS3). Hematoxylin & eosin (HE) staining (A) and negative control (D). Original magnifica-
tion x200
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3.3  clinicopathological associations
IFNAR-1 and IFNAR-2c receptor expression was associated with age, gender, tumor location 
(pancreatic head, ampulla or distal bile duct), tumor diameter, tumor grade (well, moder-
ately and poorly differentiated), tumor (T) and lymph node (N) staging, resection margins, 
tumor stage, vascular invasion and perineural invasion. No significant correlations were 
found between the above-mentioned factors and receptor expression in tumors of both 
pancreatic as periampullary cancer patients (data not shown). Since the type-I IFN receptor 
complex is composed of the IFNAR-1 and IFNAR-2c we also determined the associations 
between any of these factors and the combination of IFNAR-1 and IFNAR-2c. None of the 
clinical or pathological factors were associated with the combination of IFNAR-1 and IFNAR-
2c. Furthermore, no statistically significant differences in IFNAR-1 and/or IFNAR-2c receptor 
expression were found between the pancreatic and the periampullary cancer patients.
figure 3. Kaplan Meier curves of overall survival (OS) of patients with pancreatic cancer (straight line) and 
periampullary cancer (dotted line) show a significant survival benefit favoring patients with periampul-
lary cancer (p<0.001).
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3.4  survival analysis
5 years after intentional curative resection, 46 deaths (98%) were observed in the group 
of pancreatic cancer patients compared to 38 (70%) deaths in the group of periampullary 
cancer patients. A significant better overall 5-year survival was found in the periampullary 
cancer group versus the pancreatic cancer group (median survival was 21 vs. 13 months; 
log-rank p<0.001) (Fig.3).
Factors associated with survival were included in the univariate analysis. Variables 
with a p-value of 0.10 or less were also incorporated into the multivariate analysis. In the 
group of 47 pancreatic cancer patients univariate analysis revealed that age (p=0.024) and 
table 2a. Univariate and multivariate analysis of various prognostic parameters for survival in 47 pancre-
atic cancer patients.
Prognostic parameters
 univariate analysis multivariate analysis
 hr (95% ci)  p  hr (95% ci)  p
Age 1.04 (1.01-1.08) 0.024* 1.03 (0.99-1.06) 0.117
Adjuvant treatment 0.63 (0.32-1.25) 0.190
Tumor locationa 1.22 (0.37-3.97) 0.746
Tumor diameter 1.30 (0.90-1.89) 0.162
Grade 0.732
G1 0.70 (0.15-3.23) 0.651
G2 0.76 (0.38-1.53) 0.321
G3 1.00
Primary tumor 0.332
T1 0.12 (0.01-1.39) 0.089
T2 0.39 (0.08-2.02) 0.264
T3 0.47 (0.11-2.01) 0.308
T4 1.00
Regional Lymph nodes 1.74 (0.92-3.29) 0.090 1.60 (0.79-3.26) 0.192
Resection margins 1.05 (0.55-2.01) 0.884
Vascular invasion 1.36 (0.69-2.70) 0.376
Perineural invasion 0.96 (0.52-1.80) 0.908
IFNAR-1 score 0.91 (0.83-0.99) 0.033* 0.92 (0.83-1.03) 0.137
IFNAR-2c score 0.94 (0.84-1.05) 0.254 1.05 (0.90-1.20) 0.604
a head vs other
* Statistically significant
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IFNAR-1 receptor expression (p =0.033) were significant associated with overall survival. 
After multivariate analysis no significant correlations were found (Table 2a). In the univari-
ate analysis of prognostic factors for survival in 54 periampullary cancer patients primary 
tumor stage (T) (p=0.033) and vascular invasion (p=0.039) were significantly associated 
with survival. After including the eligible prognostic factors into the multivariate model no 
significant associations were found (Table 2b). Furthermore, Kaplan-Meier survival analysis 
was preformed but showed no statistically significant survival benefit of IFNAR-1 or IFNAR-
2c receptor expression in both pancreatic and periampullary cancer patients (figure  not 
shown).
table 2b. Univariate and multivariate analysis of various prognostic parameters for survival in 54 periam-
pullary cancer patients.
Prognostic parameters
 univariate analysis multivariate analysis
 hr (95% ci)  p  hr (95% ci)  p
Age 1.01 (0.98-1.05) 0.369
Adjuvant treatment 0.59 (0.30-1.15) 0.123
Tumor locationa 0.81 (0.43-1.52) 0.512
Tumor diameter 1.31 (0.96-1.78) 0.085 1.06 (0.73-1.56) 0.752
Grade 0.155
G1 0.76 (0.25-2.30) 0.625
G2 0.76 (0.28-1.01) 0.055
G3 1.00
Primary tumor 0.033* 0.321
T1 0.10 (0.01-0.81) 0.030* 0.29 (0.03-3.19) 0.312
T2 0.34 (0.14-0.84) 0.020* 0.55 (0.16-1.90) 0.346
T3 0.69 (0.34-1.39) 0.301 1.18 (0.45-3.11) 0.742
T4 1.00 1.00
Regional Lymph nodes 1.73 (0.89-3.33) 0.104
Resection margins 1.79 (0.74-4.29) 0.194
Vascular invasion 2.38 (1.05-5.44) 0.039* 2.11 (0.63-7.07) 0.227
Perineural invasion 1.83 (0.99-3.36) 0.053 1.42 (0.63 -3.24) 0.402
IFNAR-1 score 1.01 (0.93-1.09) 0.906 1.00 (0.90-1.11) 0.941
IFNAR-2c score 0.97 (0.86-1.09) 0.644 0.96 (0.83-1.12) 0.607
a ampulla vs distal bile duct
* Statistically significant
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4.  discussion
Type I IFNs (e.g. IFN-α, -β) are cytokines that are able to modulate several anti-tumor de-
fense processes like inducing apoptosis, cell cycle blocking and sensitizing tumor cells for 
chemo- and radiotherapy3,4,21,22 Currently, IFN-α have been used clinically for the treatment 
of several malignancies like chronic myeloid leukemia, metastatic melanoma, renal cell 
carcinoma and Kaposi sarcoma23,24 IFN-β is only used in the treatment of multiple sclerosis25.
Type I IFNs act via the type I IFN receptor complex which is composed by two subunits; 
IFNAR-1 and IFNAR-2 of which there are three isoforms that are differently spliced from a 
common gene. IFNAR-2a is the soluble form and can act as a dominant negative regulator of 
free IFNs, IFNAR-2b is a shorter form lacking regions of the cytoplasmic domain and unable 
to activate JAK-STAT signaling once the receptor binds IFNs. IFNAR-c contains the entire 
cytoplasmic domain and along with IFNAR-1 make up a functional IFN receptor complex, 
binding IFNs and inducing JAK-STAT signaling5,26.
A number of clinical studies have been conducted regarding adjuvant IFN-α therapy in 
the treatment of pancreatic cancer6-8,10,12,27 The study of Picozzi et al. reported a remarkable 
2- and 5-year survival of respectively 64% and 55%. Three studies showed similar findings, 
but they were all non-randomized studies7,9,10. Furthermore in all studies the majority of 
treated patients suffered from severe treatment toxicities. Although the importance of IFN 
receptor expression for the anti-cancer effect of IFNs has been described for fibrosarcoma, 
melanoma, breast cancer and hepatocellular cancer cells, IFN receptor status was not known 
in any of the patients receiving adjuvant IFN-α treatment 3,28. In addition, in a recent study 
we demonstrated, in a panel of 11 human pancreatic cancer cell lines, that the maximal in-
hibitory effect of IFN-α is positively correlated with the IFNAR-1 mRNA and IFNAR-2c mRNA 
and protein expression29 As a result, it is possible that the lack of IFN receptor expression 
resulted in a non-response to adjuvant IFN-α treatment.
The aim of this study was therefore to determine the type I IFN receptor expression in 
tissue of pancreatic as well as in tissue of periampullary cancer patients (ampullary and 
distal bile duct cancer), since the latter is accounting for 53% of the surgical operable pan-
creaticoduodenal tumors30. Furthermore, we correlated the interferon receptor status with 
clinicopathological factors and overall survival.
As described in literature, our study confirms that periampullary cancer patients have a 
significant favorable survival compared to pancreatic cancer patients. Furthermore, primary 
tumor stage is of prognostic value in patients with pancreatic cancer. In our study we found 
a trend towards a better prognosis in patients with a lower tumor stage, however, this did 
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not reach statistical significance. This might be explained by the relative low number of pa-
tients in the pT1 and pT4 group. Although we found a considerable inter- and intratumoral 
variability of type I IFN receptor expression in the pancreatic and periampullary cancer 
tissue, no statistically significant differences were found in the level of interferon expres-
sion between the pancreatic and periampullary cancer patients. The survival benefit of 
periampullary cancer patients can therefore not be explained by a discrepancy in interferon 
receptor expression.
In the group of pancreatic cancer patients 91.5% of the tumors had a positive expres-
sion of the IFNAR-1, of which 23.4% was strongly positive. Regarding IFNAR-2c expression, 
68.1% of the tumors showed a positive receptor expression, of which only 4.3% was strong 
positive. In the group of periampullary cancer patients, positive IFNAR-1 expression was 
found in 88.9% of the tumors of which 13% was strong positive. Regarding IFNAR-2c expres-
sion, 68.5% of the tumors in these patients positively expressed this receptor subunit, but 
none showed strongly elevated IFNAR-2c expression. Finally, expression of the IFNAR-1 and 
IFNAR-2c subunits did not correlate with any clinical, pathological or prognostic factors 
evaluated in pancreatic or periampullary cancer patients. Nevertheless, determination of 
the expression levels of type I IFN receptors in pancreatic cancer can be of value for the 
selection of patients that might benefit from adjuvant IFN-α therapy. On the other hand, in 
our above- mentioned recent study we demonstrated that the direct anti-tumor effects of 
IFN-β compared to IFN-α are much more potent and less dependent on the level of recep-
tor expression29. Moreover, van Weerd et al. described recently that IFN-β is able to exert 
its direct effects via the IFNAR-1 receptor independently of the IFNAR-2c receptor31. Taken 
these observations together and the fact that more tumors of pancreatic and periampullary 
cancer patients showed a positive, as well as a stronger positive, expression of the IFNAR-1 
receptor, compared to the IFNAR-2c receptor, adjuvant IFN-β therapy might be promising. 
In addition, it should be realized that besides the direct anti-tumor effects, type I IFNs are 
also known to have several indirect effects, like the activation of the immune system (cy-
totoxic t-lymphocytes, NK-cells and monocytes), the regulation of cytokine production, as 
well as the inhibition of angiogenesis ( inhibition of endothelial cell proliferation and VEGF 
transcription and secretion)32
Two previous studies investigated IFNAR-2 expression in pancreatic cancer tissue. The 
study of Ota et al.33 showed expression of the IFNAR-2 in 25% of the tumors, in the study 
of Saidi et al.34 IFNAR-2 expression was found in 24% of the tumors, which are both lower 
percentages compared with our study. This discrepancy could be due to the use of differ-
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ent scoring systems and/or the antibodies that were used. Both studies used a polyclonal 
antibody to stain and determine the IFNAR-2 receptor. This may be associated with less 
distinctiveness and a lower target to background ratio compared to the monoclonal anti-
body used in our study. In addition, in both studies it was not indicated which isoform of the 
IFNAR-2 receptor was detected with the antibodies that were used.
Evidently, our study has its limitations as well. This study is of retrospective nature which 
may have caused incomplete and inaccurate documentation. Another limitation can be 
found in the semi-quantitative immunohistochemical analysis of the tissue sections, which 
was subjective and thereby limited the comparability. Furthermore, the number of patients 
in our series is relatively low.
In conclusion, this is the first immunohistochemistry-based study that determined the 
IFNAR-1 and IFNAR-2c receptor expression in pancreatic and periampullary cancer tissue. 
IFNAR-1 and IFNAR-2c receptors are expressed in human pancreatic and periampullary can-
cer tissue although with great inter- intratumoral variability. Only in a small proportion of 
patients in this study the tumors strongly express the IFNAR-1 and/or IFNAR-2c. In order to 
demonstrate the relationship between interferon receptor expression and the anti-tumor 
activities of type I IFNs in pancreatic and periampullary cancer patients, prospective studies 
are necessary.
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1.  Pancreatic cancer
Pancreatic cancer has a dismal prognosis with mortality rates almost equaling the incidence 
and is characterized by its insidious onset and late diagnosis1. Surgery is the only curative 
therapy, but at time of presentation over 80% of the patients are diagnosed with locally ad-
vanced or metastatic disease, excluding them from curative resection. Nevertheless, even 
after intentional curative radical surgery, due to the high recurrence rate, prognosis remains 
poor resulting in an overall 5-year survival rate of less than 6%2. With the evaluation of the 
efficacy of adjuvant chemo- and radiotherapy in several clinical trials, an attempt have been 
made to improve survival. However, since the introduction of gemcitabine survival rates 
have barely been improved and the role of adjuvant treatment in pancreatic cancer remains 
an area of conflict3-5.
It is stated that characteristics of pancreatic cancer such as the tumor stroma, restricted 
vasculature and a hypoxic environment may prevent delivery of chemotherapy to tumor 
cells, thereby explaining the limited benefits of adjuvant treatment6. Therefore, in order 
to improve outcome other treatment strategies such as neoadjuvant therapies7, immune 
modulating therapies8, tumor-stroma targeting therapies9 and the addition of biological 
response modifiers like interferons10-14, have been attempted. The last decade several clini-
cal studies provided some evidence that there might be a role for adjuvant IFN-α therapy 
in the treatment of pancreatic cancer. Despite encouraging data that were reported, the 
study design of most of the conducted studies was not very refined and in all studies treat-
ment toxicities were notably high10-13. Additionally, the only phase III trial evaluating the 
use of adjuvant IFN-α, the CapRI trial (Combined Chemoradioimmunotherapy for Pancreatic 
Adenocarcinoma), did not demonstrate a significant survival benefit for patients in the 
experimental arm. Nevertheless, there was a difference in median survival of 3,6 months 
which implies that probably some patients benefited from the experimental treatment14. 
However, before start of these studies, certain aspects of interferon therapy, such as the 
relevance of the interferon receptors and the use of other type I interferons, such as IFN-β, 
were not addressed. Therefore, the main aim of this thesis was to further elucidate the role 
of interferon therapy in the treatment of pancreatic cancer.
2.  interferons
Type I IFNs ( e.g. IFN-α, IFN-β and IFN- ω) are cytokines that are known to have antipro-
liferative, antiviral and immunoregulatory activities. Additionally, they are involved in cell 
differentiation and anti-tumor defense processes. These anti-tumor processes can either be 
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direct, by the stimulation of apoptosis and blocking of cell cycle, or indirect by the activa-
tion of natural killer cells, T-cells and macrophages. Furthermore, type I IFNs are able to 
sensitize tumor cells for chemo- and radiotherapy by inducing a cell cycle arrest at the G1 
phase, or by the prolongation and accumulation of cells in the S-phase15-17. Type I IFNs act 
via the type I IFN receptor complex of which IFNAR-1 and IFNAR-2c are the most important 
subunits18,19.
In the early days, IFN-α was approved and used in the treatment of hairy cell leukemia, 
chronic myelogenous leukemia, multiple myeloma, malignant cutaneous melanoma, Kapo-
si’s sarcoma, gastroenteropancreatic neuroendocrine tumors and renal cell carcinoma20-26. 
However, due to the increased understanding of molecular mechanisms of various types of 
cancers nowadays IFN-α is primarily used in the treatment of metastatic renal cell carcinoma 
and malignant melanoma. At present, IFN-β is only approved in the treatment of relapsing 
remitting multiple sclerosis (RRMS).
3.  interferons in the treatment of Pancreatic cancer
Although clinical studies regarding adjuvant IFN-α therapy in the treatment of pancreatic 
cancer have already been conducted, several aspects of interferon therapy were not ad-
dressed. Despite promising results reported regarding IFN-β therapy, very few studies 
investigated the effect of IFN-β15,27-29. Furthermore, the relationship between the amount of 
type I IFN receptors expressed and the anti-tumor effects of IFN-α and IFN-β in pancreatic 
cancer cell lines is not established. Therefore, as described in chapter 2, we first determined 
the anti-tumor potencies of IFN-α and  –β in a large panel of pancreatic cancer cell lines 
and assessed the correlation between the responsiveness to type I IFNs and the expression 
of IFNAR-1 and IFNAR-2c. In this study a considerable variability in both type I interferon 
receptor expression and in the response to type I IFNs was demonstrated. However, the 
anti-tumor activity (i.e. induction of apoptosis and inhibition of cell proliferation) of IFN-β 
was significantly more potent, already at low concentrations, compared to with IFN-α. The 
maximal inhibitory effect induced by IFN-α was significantly correlated with the level of 
IFNAR-1 and IFNAR-2c receptors expressed. On the other hand, this was not the case for 
IFN-β. This can be explained by the fact that IFN-β has a 10-fold higher binding affinity with 
the receptor complex compared to IFN-α and, additionally, is capable of inducing functional 
signal transduction via the IFNAR-1, independently of the IFNAR-2c receptor in which a 104 
unique set of genes is induced30,31. Nevertheless, the potent anti-tumor activities of IFN-β 
were clearly shown and it is demonstrated that the expression of type I IFN receptors in 
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pancreatic cancer can be of predictive value in the responsiveness to the growth inhibitory 
effects of IFN-α.
Given these observations, it is surprising that in none of the patients treated with 
adjuvant IFN-α in clinical trials, before start of treatment in the resection specimens, the 
tumoral type I IFN receptor expression was assessed. The knowledge of type I IFN receptor 
expression is of importance and may prevent unnecessary, often toxic, treatments in these 
cancer patients. Therefore, in chapter 5, the type I IFN receptor expression (i.e. IFNAR-1 and 
IFNAR-2c) was determined in tissue of pancreatic cancer, as well as in tissue of periampul-
lary cancer patients (ampullary and distal bile duct cancer), since the latter is accounting 
for 53% of the surgical operable pancreaticoduodenal tumors and are known to have dif-
ferent prognosis32-34. Although our study was of retrospective nature and the number of 
patients were relatively low, this study did demonstrate, for the first time, that both IFNAR-1 
as IFNAR-2c receptor are expressed in human pancreatic and periampullary cancer tissue. 
However, interferon receptors were expressed with great inter-and intratumoral variability 
and, unfortunately, only a small proportion of the tumors strongly expressed the IFNAR-1 
and/or IFNAR-2c. These observations may explain the differences found in the clinical 
studies regarding adjuvant IFN-α therapy. However, as depicted previously, the anti-tumor 
effects of IFN-β are more potent and less dependent on the level, and subunit, of receptors 
expressed. Additionally, it has been demonstrated that IFN-β can induce functional signal 
transduction, via the IFNAR-1, independently of the IFNAR-2c receptor. On this basis, adju-
vant IFN-β therapy seems more promising as more tumors of pancreatic and periampullary 
cancer patients showed a positive, as well as stronger positive, expression of the IFNAR-1 
compared to the IFNAR-2c receptor. Nevertheless, since at present it is unknown what the 
relationship between interferon receptor expression and the anti-tumor activities of type I 
IFNs in pancreatic and periampullary cancer patients is. Therefore, prospective studies are 
necessary.
In cancer tissue general, thus including pancreatic cancer, growth factors and their 
receptors, like insulin and insulin-like growth factor (IGF) receptors are frequently overex-
pressed35-37. In pancreatic cancer, the overexpression of the IGF1 receptor (IGF1R) is even 
associated with more proliferating and invasive tumors, leading to a poorer survival38. 
Additionally, it is becoming more evident that high levels of insulin can stimulate tumor 
growth. As such, the role of insulin and the insulin receptor, which is also closely related to 
the IGF-system and can interact with each other’s receptors, should not be neglected39-41. 
Furthermore, as described in previous research, IFN-β is capable of modulating the IGF-
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system in neuro-endocrine tumor cells42. However, no studies yet evaluated the effects of 
IFN-β with respect to the IGF and insulin system in human pancreatic cancer cells. Therefore, 
depicted in chapter 3, we investigated, in addition to the effects of insulin and insulin-like 
growth factors on pancreatic cancer cell proliferation and migration, the inhibitory effects 
of IFN-β on IGF- and insulin-stimulated proliferation and migration. We demonstrated that 
both IGF-1, IGF-2, as well as insulin, have potent stimulatory effects on pancreatic cancer 
cell proliferation and migration. Importantly, IFN-β is able to inhibit the IGF1-, IGF-2- and 
insulin-stimulated cell growth as well as migration. However, IFN-β is not able to inhibit 
basal cell migration and the inhibitory effects of IFN-β on growth factor stimulated cell 
migration were less pronounced compared to the effects on growth factor stimulated pro-
liferation. One of the explanations might be that associated interferon signaling pathways 
are predominately involved in cell proliferation, rather than in cell migration. Moreover, in 
the present study several aspects of the insulin and insulin-like growth factor systems, like 
for example the role of the family of IGF binding proteins and the involvement of different 
molecular pathways in cancer cell proliferation and migration, remain underexposed. Nev-
ertheless, results from this study further favor the use of IFN-β as part of treatment options 
for patients with pancreatic cancer.
Generally, before the start of clinical studies, treatment effects have to be evaluated 
in vivo as well. Therefore, in chapter 4, the effects of IFN-β alone, and combined with the 
golden standard chemotherapeutic agent in pancreatic cancer gemcitabine, were evaluated 
in a heterotopic subcutaneous pancreatic cancer mouse model4. Additionally, the effects of 
combined treatment were first evaluated in vitro and demonstrated a potent synergistic 
effect of IFN-β combined with gemcitabine. On the basis of these results, it was decided 
to lower the concentration of gemcitabine in vivo to a suboptimal dose. After 30 days of 
treatment, tumors of mice treated with the combination of IFN-β and gemcitabine were 
statistically significantly smaller compared to the control. Additionally, we demonstrated 
in these tumors by immunohistochemistry, a statistically significant lower proportion of 
proliferating and a clear trend towards an increased proportion of apoptotic cells. The 
combined treatment was well tolerated. In contrast to the effects of IFN-β in vitro, in vivo 
IFN-β monotherapy showed no statistically significant inhibitory effect on tumor growth, 
although the percentage of proliferating tumor cells was significantly reduced. In vitro, for 
the BxPC-3 cell line the concentration required to reduce cell growth with 50% was 114 IU/
ml. With respect a large panel of cell lines the required concentration ranged from 70-1000 
IU/ml43. However, in clinical settings these concentrations seem not easily reached (4.0 IU/
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ml after four doses of 18 MIU IFN-β at 48-h intervals in serum of human healthy volunteers 
after s.c. administration)44. As mentioned before, the predictive value of the IFN receptor 
expressed in pancreatic cancer tissue for efficacy of interferon therapy has not been estab-
lished. Furthermore, although considered as the backbone in adjuvant pancreatic cancer 
treatment, the success of gemcitabine is disappointingly low, with response rates of less 
than 20%. Therefore it would be desirable, in order to prevent unnecessary treatment toxici-
ties, to predict the response to treatment before start of therapy. In this respect, one could 
think of the use of molecular markers, such as microRNA (miRNA) or circulating proteins 
in order to predict the treatment sensitivity. In the literature several miRNA have been 
investigated for their role in chemoresistance in pancreatic cancer of which some selected 
miRNAs (-15a, -21, -34, -200b, -200c, -214 and -221) showed promising results. However, 
the consequence of modifications in miRNA expression and their prognostic value in the 
clinical setting is still unclear45. With regard to the prediction of the effect of interferons the 
presence of the circulating free interferon receptor (IFNAR-2a) seems interesting. In serum 
of cancer patients the presence of the IFNAR-2a receptor has been demonstrated, however, 
it is unknown what the clinical significance, with respect to the effect of interferon therapy, 
in pre-clinical and clinical setting46-48. Nevertheless, at present, the use of biomarkers in 
order to predict the effect of treatment is still wishful thinking. More promising seems the 
use of an ex vivo tissue slice model. By the use of this technique it is possible to culture with 
good viability, up to 4 days very thin (200µm) slices of human resection specimens, like for 
example pancreatic cancer (Figure  1), and to evaluate multiple treatments in one tumor 
sample. The use of the tissue slice model in pancreatic cancer (evaluation of gene-therapy 
and the influence of pancreatic stellate cells) has been described before and showed 
promising results49,50. In chapter 4 the ex vivo tissue slice technique was used as well and 
demonstrated encouraging results. After 3 days of incubation with different therapeutic 
figure 1: Tissue slicer machine (A) and hematoxylin and eosin stained coupes of tissue slices of human 
pancreatic cancer resection specimen (B and C) and periampullary cancer resection specimen (D) after 72 
hours of culture. Original magnification x100 (B), x200 (C), x300 (D).
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agents, although not yet validated, a very clear morphological difference in tissue structure 
was observed, particularly pronounced in the tissue slices that were incubated with the 
combination of IFN-β and gemcitabine. Given this pronounced effect of the therapeutic 
agents on the tissue structure, in future, the validation of the effects of treatment is chal-
lenging. While the use of an ex vivo tissue slice model to predict treatment effects seems 
promising there are still some major challenges, like the determination of the concentra-
tion of treatment compounds comparable between ex vivo as well as in the clinical setting. 
Furthermore, the validation of the effects of drug treatment remains challenging and needs 
to be elaborated before this method can be used in clinical setting.
4.  challenges and future PersPectives
Although a major part of the potential anti-cancer effects of type I IFNs, especially IFN-β, 
have been highlighted in this thesis, some important aspects of interferon therapy have 
not been addressed yet.
Nowadays it is becoming evident that the immune system is capable of detecting 
tumor antigens and to initiate humoral and cellular responses to track and eliminate these 
transformed cells and thereby inhibiting tumor development. Nevertheless, some tumor 
cells have already been evolved and able to escape the immunosurveillance creating tu-
mors with reduced immune responsiveness and greater potential to grow in an inflamed 
microenvironment51,52. This concept is called cancer immunoediting and its relevance is 
becoming more clear53. As mentioned before, type I interferons are also known to have 
indirect effects like the activation of NK-cells, t-cells and macrophages, and addition-
ally, it has been demonstrated that type I IFNs have crucial roles in promoting the host 
anti-tumor immunity54,55. In a clinical trial of adjuvant IFN-α therapy in the treatment of 
malignant melanoma it is demonstrated that patients who develop autoantibodies or 
clinical manifestations of autoimmunity had significant longer overall and relapse free 
survival compared to patients who did not develop symptoms or signs of autoimmunity56. 
Therefore, although not studied in this thesis but interesting for future research would be 
the interaction between pancreatic cancer cells, the immune system and interferons in 
for example an orthotopic pancreatic cancer model in mice with intact immune system. 
Additionally, it has been described that multiple tumor types, like ovarian, breast, colon, 
prostate, bladder, glioblastoma and hepatocellular carcinoma, express increased levels of 
cell surface proteins, like CD47, allowing cancer cells to avoid phagocytosis and to escape 
the innate immune system surveillance57. In addition, recent preliminary data showed that 
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human pancreatic adenocarcinomas express elevated levels of CD47 as well58. In this re-
spect it can be hypothesized that blocking CD47 in combination with the use of type I IFNs, 
could enhance the immunomodulatory host effects of patients with pancreatic cancer. Cur-
rently, the recently developed humanized anti-CD47 antibody, Hu5F9-G4 is being tested in 
a Phase I trial (A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With 
Advanced Solid Malignancies; NCT02216409).
A major challenge of interferon therapy is the induction and activation of several cancer 
cell survival pathways, limiting the anti-cancer effects of interferons. Survival pathways in-
duced by IFNs include the activation of nuclear factor kappa-beta (NF-κB), the dephosphor-
ylation of specific protein tyrosine phosphatases (PTPs), the over activation of G1P3 and a 
decrease in cyclic adenosine monophosphate (cAMP). However, one of the main resistance 
mechanisms that have been extensively described includes the JAK-2/STAT-3 pathway59,60. 
In addition to phosphorylation and activation of STAT-1 and STAT-2, type I IFNs are also 
able to activate and phosphorylate the STAT-3 protein which can act as an adaptor of the 
phosphatidylinositol 3 kinase (PI3K) and activates it’s downstream target Akt, important for 
the anti-apoptotic signals. A recently demonstrated potential strategy to counteract the 
STAT-3 induced escape mechanism is via the activation of peroxisome proliferator-activated 
receptor-γ (PPAR- γ). PPAR-γ is one of the main targets of insulin sensitizing drugs. On the 
other hand PPAR-γ agonists, like troglitazone, also display antineoplastic effects in several 
tumors, including pancreatic cancer. Additionally, in pancreatic cancer cells, it can oppose 
the STAT-3 dependent escape mechanism induced by type I interferons and thereby con-
sequently increase cell death61,62. Furthermore, interferons can induce a stress response in 
which the expression and signalling activity of the epidermal growth factor (EGF) receptor 
is enhanced providing an escape mechanism to the growth inhibition induced by IFN-α. 
Besides that, EGF has been shown to have a protective effect on IFN-α induced apoptosis. 
In order to overcome these survival mechanisms the use of specific inhibitors may be 
considered, for example the farnesyl-transferase inhibitor R115777 or the tyrosine kinase 
inhibitor Gefitinib, which both have shown promising results enhancing the anti-tumor 
activity of type I IFNs in head and neck squamous cell carcinomas and human epidermoid 
cancer cells63,64.
Another major challenge limiting the clinical implication of IFN therapy in the treat-
ment of pancreatic cancer is the short half-life of IFNs. However, advantage can be gained 
from PEGylated forms of IFN-α and –β, in which lower and less frequent doses are necessary 
compared to the conventional IFNs. The PEGylated form of IFN-α has already proven to 
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be effective in the treatment of grade III melanoma65 and metastatic renal cell carcinoma 
patients66. Currently, a newly developed PEGylated form of IFN-β is being tested in a phase 
III clinical trial (ADVANCE) in patients with multiple sclerosis. 67,68. This PEGylated form of 
IFN-β reached, in an experimental model, still 20 hours after a single s.c. dose of 3.0 MIU/
kg in monkeys a serum concentrations of 100 IU/ml and thereby seems very promising as 
additional therapy in the treatment of pancreatic cancer.
5.  general considerations and concluding remarks
Although promising data regarding adjuvant IFN-β therapy in the treatment of pancreatic 
cancer have been shown in this thesis, it has also been demonstrated that monotherapy 
is inadequate in pancreatic cancer and combination therapies should be attempted. The 
considerable degree of heterogeneity of pancreatic cancer is demonstrated in this thesis as 
well, which makes it difficult, perhaps impossible, to find one optimal treatment strategy. 
For example, in the optimal setting, tumors with very rich tumor stroma need to be treated 
differently, for instance with a c-met inhibitor69, compared to tumors with less tumor-stroma 
but an abundant expression of the IGF1R, which can possibly be targeted with the newly 
developed tyrosine-kinase inhibitor OSI-90670-72. Future prospective studies are necessary 
to demonstrate the beneficial effect of IFN-β, although the enhancement of chemo- and 
radiosensitivity is not absolutely receptor specific, it should be considered to determine 
the IFN receptor expression in pancreatic cancer tissue prior to therapy. In the purpose of a 
more patient approached medicine, the development of the tissue slice technique seems 
promising, and could be useful in determining the effects of interferon in combination with 
gemcitabine or other chemotherapeutic agents before start of treatment. On the other 
hand, using this technique, the effect of IFN-β on the immune system cannot be deter-
mined. Nevertheless, despite the expressed concerns and possible topics that still can be 
elaborated, this thesis demonstrated promising results with regard to the use of IFN-β in 
the treatment of pancreatic cancer and provides a sufficient basis for the next step, a future 
prospective clinical study.
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Pancreatic cancer is a highly aggressive malignancy with limited treatment options. Over 
the last 30 years survival rates have barely been approved and research has focused on 
other treatment modalities like biological modulators such as type I interferons (IFNs). Type 
I IFNs (i.e. IFN-α and –β) are known to have antiproliferative, antiviral and immunoregula-
tory activities. In addition, they are also able to induce apoptosis, exert cell cycle arrest 
and thereby sensitize tumor cells for chemo- and radiotherapy. A few years ago several in 
vitro, in vivo and clinical studies have been conducted evaluating adjuvant IFN-α therapy 
after curative resection of pancreatic cancer and although these studies showed promising 
results, the only randomized clinical trial did not demonstrate a significant survival benefit 
for patients receiving adjuvant IFN-α treatment. Therefore, to date, the use of interferons 
in the treatment of pancreatic cancer remains controversial. Nevertheless, before the start 
of these clinical studies, certain aspects of interferon therapy, such as the relevance of the 
interferon receptors, the importance of growth factors and the potential use of IFN-β were 
not addressed. In this thesis we aimed to further investigate the role of interferon therapy 
in the treatment of pancreatic cancer.
chapter 1, the general introduction, describes the challenges regarding the treatment 
of pancreatic cancer and provides information about type I interferons and their use in can-
cer treatment. In particular, this chapter highlights the current knowledge of interferon use 
in the treatment of pancreatic. Chapter 1 ends with the objective and outline of this thesis.
In chapter 2 the anti-tumor potencies of IFN-α and –β were determined in a panel of 11 
human pancreatic cancer cell lines. Additionally, the correlation between the responsive-
ness to type I IFNs and the expression of the interferons receptors, IFNAR-1 and IFNAR-2c, 
was evaluated. In this study a considerable variability between pancreatic cancer cell lines 
in the expression of type I IFN receptors and in the response to type I IFNs was found. We 
demonstrated a significant positive correlation between the inhibitory effect of IFN-α and 
the level of IFNAR-1 and IFNAR-2c receptors expressed, indicating that these receptors can 
be of predictive value for the responsiveness to IFN-α therapy. No correlation was found 
between receptor expression and the responsiveness to IFN-β. Interestingly, the anti-tumor 
activity (i.e. the induction of apoptosis and inhibition of cell proliferation) of IFN-β was 
significantly more potent, already at low concentrations, and less dependent interferon re-
ceptor expression, compared to the anti-tumor activities of IFN-α. In this study we therefore 
conclude that the use of IFN-β in the treatment of pancreatic cancer seems more promising 
than IFN-α.
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In chapter 3 the effects of IFN-β with respect to the insulin and insulin-like growth factor 
system in human pancreatic cancer cells is evaluated. In cancer tissue in general, and thus 
in pancreatic cancer as well, insulin and insulin-like growth factors and their receptors are 
frequently overexpressed, leading to more invasive and proliferating tumors and eventually 
to a worse prognosis. In the in vitro studies described in chapter 3 we demonstrated that 
both IGF1, -2 and insulin have potent stimulatory effects on pancreatic cancer cell prolifera-
tion and migration. We showed that IFN-β is able to inhibit this growth factor stimulated 
cell growth and migration. Although the effects of IFN-β on insulin- and IGF-stimulated cell 
migration were less pronounced compared to its effects on proliferation, this study further 
favors the use of IFN-β as a part of the treatment for patients with pancreatic cancer.
chapter 4 demonstrates the potent anti-tumor effects of IFN-β combined with gem-
citabine in vitro, in vivo and ex vivo. In this study the synergistic effects of IFN-β combined 
with gemcitabine were first demonstrated in vitro. Thereafter, in a heterotopic pancreatic 
cancer mouse model, mice were treated with IFN-β alone or combined with a suboptimal 
concentration of gemcitabine. It was found that the tumor volume of mice treated for 
30-days with the combination of interferon and gemcitabine was significantly smaller com-
pared to the control. Furthermore, an ex vivo tissue slice model demonstrated at histological 
level potent effects of IFN-β and gemcitabine combination treatment as well. These positive 
results argue for well-substantiated research in the clinical setting.
In chapter 5 the type I IFN receptor expression in human pancreatic and periampullary 
cancer tissue was determined. In order to establish a direct antitumor effect the expres-
sion of the type I IFN receptor, IFNAR-1 and IFNAR-2c is of importance. In this study we 
demonstrated that the IFNAR-1 and IFNAR-2c receptors are expressed in pancreatic and 
periampullary cancer tissue, although with great inter- and intratumoral variability. Recep-
tor expression was not correlated with any clinicopathological factors or with survival. 
Furthermore, we demonstrated that, in both types of tumors, only a small percentage of 
the patients showed a strong expression of the IFNAR-1 and IFNAR-2c, which could pos-
sibly explain the differences found in the clinical studies regarding adjuvant IFN-α therapy. 
Nevertheless, prospective studies are necessary to demonstrate the relationship between 
the IFN receptor expression and the antitumor activities of type I IFNs in pancreatic and 
periampullary cancer patients.
chapter 6, the general discussion, provides an overview and discusses the findings 
from the previous chapters. Moreover, the challenges and future perspectives regarding 
adjuvant IFN therapy are discussed. Some major issues like the induction of tumor cell 
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pointed out in this chapter. Finally, some general considerations and remarks are given.
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Alvleesklierkanker, oftewel het pancreascarcinoom, is met een totale 5-jaars overleving van 
minder dan 6% de 4e kanker gerelateerde doodsoorzaak in de westerse wereld. Chirurgische 
resectie is de enige curatieve behandeling echter, door vroege metastasen en/of lokaal 
uitgebreide ziekte, komt op het moment van de diagnose maar 15-20% van de patiënten in 
aanmerking voor een in opzet curatieve therapie. Ondanks jaren van uitgebreid onderzoek 
blijkt aanvullende (adjuvante) chemo- en/of radiotherapie slechts een zeer beperkte toege-
voegde waarde te hebben en is de overleving van patiënten met een pancreascarcinoom 
de afgelopen jaren nauwelijks verbeterd. Onderzoek heeft zich daarom gericht op het 
toevoegen van andere behandelingsmogelijkheden, waaronder biologische modulatoren 
zoals type I interferonen (IFN-α/IFN-β), aan de bestaande behandelingen. Interferonen zijn 
lichaamseigen eiwitten, behorend tot de groep van cytokinen, die o.a. worden afgeschei-
den door het immuunsysteem na contact met een virus, bacterie of schimmel. Interferonen 
hebben een antivirale, antiproliferatieve en immuun regulerende werking en zijn daarnaast 
ook in staat om apoptose te induceren en de cel cyclus te blokkeren waardoor kankercellen 
gevoeliger kunnen worden voor chemo- en radiotherapie. Type I Interferonen oefenen hun 
werking uit via de type I IFN receptor, hetgeen voornamelijk bestaat uit een signalerend 
deel (IFNAR-1) en een IFN-bindend deel (IFNAR-2c). De toegevoegde waarde van IFN-α the-
rapie aan de bestaande behandeling van het pancreascarcinoom is enkele jaren geleden 
door verschillende onderzoeksgroepen onderzocht. De klinische studies lieten, afgezien 
van de grote hoeveelheid bijwerkingen, indrukwekkende resultaten zien met toegenomen 
overleving voor patiënten die de adjuvante IFN-α behandeling ondergingen. De enige 
gerandomiseerde klinische studie liet echter geen significant toegenomen overleving zien, 
al lijkt het er op dat in de experimentele behandelingsarm er patiënten zijn die wel ge-
profiteerd hebben van de aanvullende IFN-α behandeling. Desalniettemin is tot op heden 
het gebruik van IFN-α, in de behandeling van het pancreascarcinoom, gezien de mate van 
bijwerkingen, tegenstrijdig. Voor de start van deze klinische studies waren er verschillende 
aspecten van adjuvante IFN behandeling, zoals de relevantie van de IFN receptoren en het 
gebruik van IFN-β, echter niet onderzocht dan wel onderbelicht. Dit proefschrift heeft zich 
er daarom op gericht om de rol van interferon therapie in de behandeling van het pancre-
ascarcinoom verder te onderzoeken.
In hoofdstuk 1, de algemene inleiding, worden de uitdagingen met betrekking tot de 
behandeling van het pancreascarcinoom omschreven en informatie gegeven over type I 
interferonen en hun plaats in de behandeling van verschillende vormen van kanker. Daar-
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naast wordt specifiek de op dit moment bestaande kennis over het gebruik van interferon in 
de behandeling van het pancreascarcinoom besproken en toegelicht. Hoofdstuk 1 eindigt 
met een toelichting omtrent het doel en een overzicht van dit proefschrift.
hoofdstuk 2 laat de celgroei remmende en apoptose inducerende effecten van IFN-α 
en –β zien in 11 verschillende humane pancreas carcinoom cel lijnen. In deze studie wordt 
ook de correlatie tussen de expressie van interferon receptoren (IFNAR-1 en IFNAR-2c) 
en de mate van respons op IFN-α en –β bepaald. Er werd in deze studies een aanzienlijke 
variabiliteit in receptor expressie gevonden. Het effect van IFN-α bleek significant positief 
gecorreleerd met het aantal receptoren (IFNAR-1 en IFNAR-2c) dat tot expressie wordt ge-
bracht, hetgeen aanduidt dat deze receptoren van waarde kunnen zijn bij het voorspellen 
van de respons op IFN-α. Er werd geen correlatie gevonden tussen het aantal interferon 
receptoren dat tot expressie wordt gebracht en het effect van IFN-β. Het cel groei remmend 
en apoptose inducerend effect van IFN-β minder afhankelijk van de receptor expressie en 
vele malen krachtiger, al bij lage concentraties, dan het effect van IFN-α. Uit deze studie 
word daarom geconcludeerd dat het gebruik van IFN-β in de behandeling van het pancre-
ascarcinoom er belovender uit ziet dan het gebruik van IFN-α.
In hoofdstuk 3 worden de effecten van IFN-β op het insuline en de insulineachtige 
groeifactoren (IGF) systeem onderzocht. Bij kanker in het algemeen, en dus ook bij het pan-
creascarcinoom, worden insuline, IGFs en hun receptoren vaak overmatig op de tumorcel-
membraan tot expressie gebracht wat kan leiden tot sterkere prolifererende en invasievere 
tumoren en daardoor ook tot een slechtere prognose. De studies beschreven in hoofdstuk 
3 laten de sterke celgroei inducerende en cel migratie bevorderende effecten van zowel 
IGF-1 en IGF-2, alsmede insuline, op humane pancreascarcinoom cellen zien. De studie laat 
tevens zien dat IFN-β in staat is om deze groeifactor geïnduceerde celgroei en migratie 
significant te remmen. Ondanks het feit dat de effecten van IFN-β op de insuline- en IGF-
gestimuleerde celgroei sterker waren dan het effect op de migratie, bekrachtigt deze studie 
de veelbelovende werking van INF-β in de behandeling van het pancreascarcinoom.
hoofdstuk 4 laat de anti-tumor effecten van IFN-β gecombineerd met gemcitabine in 
vitro, in vivo en ex vivo zien. In deze studie werd eerst het synergistische effect van IFN-β 
gecombineerd met gemcitabine in vitro aangetoond. Hierna werd met behulp van een 
heterotoop subcutaan pancreascarcinoom muismodel het effect van de behandeling met 
IFN-β en een suboptimale dosis van gemcitabine aangetoond. Na 30 dagen behandeling 
was het tumorvolume van muizen behandeld met de combinatie van IFN-β en gemcitabine 
significant lager vergeleken met het tumorvolume van de controle muizen. Daarnaast werd 
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chapter 7door middel van een ex vivo tissue slice model ook op histologisch niveau de effecten van 
IFN-β en gemcitabine combinatie behandeling aangetoond. Deze veelbelovende resul-
taten geven aanleiding voor een goed onderbouwd klinisch onderzoek naar de effecten 
IFN-β combinatietherapie in patiënten met een pancreascarcinoom.
Om een effect van IFN te bewerkstelligen is expressie van de type I IFN receptor van 
belang. In hoofdstuk 5 werd daarom de type I IFN receptor expressie in tumoren van 
patiënten met een pancreas- of peri-ampullair carcinoom bepaald. Deze studie toonde aan 
dat, hoewel met enige variabiliteit, zowel het signalerende deel van de receptor (IFNAR-1) 
als het interferon bindende deel van de receptor (IFNAR-2c) tot expressie komt in humaan 
pancreas en peri-ampullair kanker weefsel. De expressie van deze receptoren was echter 
niet gecorreleerd met klinische of pathologische parameters, of met overleving. Verder 
werd middels deze studie aangetoond dat in beide type kanker maar een klein percentage 
van de patiënten tumoren hadden met een sterke expressie van de IFNAR-1 en IFNAR-2c 
receptor. Mogelijk zou dit de verschillende uitkomsten van overleving na adjuvante IFN-α 
therapie in de verschillende klinische studies kunnen verklaren. Prospectieve studies zijn 
echter nodig om de relatie tussen de IFN receptor expressie en het anti-tumor effect van 
interferonen in patiënten met een pancreas of peri-ampullair carcinoom aan te tonen.
hoofdstuk 6 betreft de algemene discussie waarin de verschillende resultaten uit 
voorgaande hoofdstukken besproken en bediscussieerd worden. Daarnaast worden de 
uitdagingen en toekomstperspectieven met betrekking tot adjuvante IFN therapie be-
sproken. Verder worden belangrijke aspecten, zoals de inductie van verschillende tumorcel 
overlevingsmechanismen, de rol van het immuunsysteem en de relatief korte half waarde 
tijd van type I IFNs in de circulatie besproken in dit hoofdstuk. Ten slotte worden er enkele 
algemene overwegingen en opmerkingen aangedragen.
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En opeens ben ik dan bij het laatste, en waarschijnlijk ook het meest gelezen deel van mijn 
proefschrift beland. Het dankwoord. Zoals vele proefschriften had ook dit proefschrift niet 
tot stand kunnen komen zonder de hulp en steun van velen, waarvan een aantal mensen 
een speciaal woord van dank verdienen.
Allereerst mijn promotoren Leo Hofland en Casper van Eijck. Leo, ik weet nog goed de eerste 
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Ondanks dat ik regelmatig sneller wilde, heb ik ervaren dat jouw nauwkeurigheid het on-
derzoek en dit proefschrift alleen maar goed heeft gedaan, dat ben ik erg gaan waarderen 
en je enorm dankbaar voor.
Casper, vanwege mijn chirurgische interesse, en natuurlijk ook via het voetbal, ben ik in 
contact met jou gekomen. De afgelopen jaren heb ik mogen ervaren wat voor enorme inzet 
jij hebt voor je patiënten, onderwijs en het onderzoek. Dit bewonder ik en soms vraag ik 
mij wel eens af waar je de tijd vandaan haalt! Op onderzoeksgebied heb ik van jou geleerd 
zelfstandig te zijn en het initiatief te nemen, iets wat mij ook nu tijdens mijn coschappen 
veel goeds heeft gebracht. Daarnaast wist jij, bij een negatief resultaat, altijd weer iets 
positief ervan te maken, wat mij weer moed gaf om door te gaan. Ik hoop in de toekomst 
ook op klinisch gebied nog veel van je te mogen leren.
Mijn dank gaat uit naar de leden van de leescommissie. Prof.dr. W.W. de Herder,
Prof.dr. C. Verhoef en Dr. K. Biermann. Dank u allen voor het beoordelen van het manuscript. 
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van de commissie Prof.dr. S. Sleijffer, Prof.dr. O.R.C. Busch en dr. J.A.M.J.L. Janssen, hartelijk 
danken voor het plaatsnemen in de commissie.
Collega’s op het lab neuro-endocrinologie! Marlijn en Diana, Aimee, Rob en Laura. Toen ik 
als master student kwam wist ik toeten noch blazen van labonderzoek. Bedankt dat jullie 
mij hebben opgevangen en wegwijs hierin hebben gemaakt. Een speciaal woord van dank 
gaat uit naar Fadime en Peter. Fadime, jij bent zo secuur in je werk, dat vind ik erg knap. 
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Door jou hebben mijn cellen zelden een besmetting of infectie gehad en als er iets niet 
klopte kon ik altijd bij jou terecht voor raad! Daarnaast heb jij mij geholpen met de laatste 
loodjes van het onderzoek waarvoor ik je eeuwig dankbaar ben! Peter, waar zal ik begin-
nen…! Wat hebben wij wat afgekletst bij de celkweek, bij de muizen, in de darkroom en 
tijdens al die ellendige migratie experimenten. Als het even niet lekker liep, kon ik bij jou 
daar ongestoord over klagen en wist jij mij uiteindelijk altijd weer een beetje op te beuren 
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De neuro-endogekkies! In het bijzonder Marije, Vincent, Sara, Sabine, Roxanne, Sanne, 
Thomas, Federico en Timon. Bedankt voor de leuke tijd die ik gehad heb op, maar ook zeker 
buiten, het lab. Ik wens jullie allemaal veel succes met jullie onderzoek en hoop sommige 
van jullie nog eens tegen te komen in de kliniek!
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weet zeker dat dit op ons van toepassing is. Ondanks dat ik soms wel eens meer inspanning 
zou willen, vind ik bij jullie zeker ontspanning en daar ben ik jullie erg dankbaar voor!
Lieve Marlieke, Kirsten, Elsbeth en Hiske. Van teamgenootjes naar inmiddels hele dierbare 
vriendinnen, en wat ben ik daar blij mee! Els, over een jaartje al huisarts en over minder 
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wachten tot ik mag oppassen! Hiske, met jouw tomeloze energie weet je ons soms enorm 
op te beuren! Ik weet zeker dat ook jij een goede huisarts gaat worden! Marlieke, samen 
naar Bali, samen naar Florida, wat was het heerlijk! Bedankt voor een altijd luisterend oor en 
goede adviezen! Veel geluk in je nieuwe huis en op naar de vele borrels en BBQ’s op jouw 
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dakterras! Kirsten, nog even en we kunnen ons 10-jarig jubileum vieren! Wat kunnen wij 
samen lekker klagen en wat lucht dat soms op, waarvoor dank! Ik wens je veel succes met je 
baan, die jou denk ik op het lijf geschreven is, en al het geluk in je prachtige huis! Lieve Caro, 
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Lieve Richelle, mijn zusje, wat ben ik trots op jou en wat ben ik blij dat jij op 10 juni achter 
mij wil staan! Je hebt een engeltje op je schouder gehad. Ondanks dat je nog een lange weg 
te gaan hebt, weet ik als geen ander dat het goed gaat komen. Als er iemand wilskracht en 
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en daar mag je enorm trots op zijn!
Opa Sjekkie, Opa Sigaar, Oma Gijs en Oma Moppie. Hoe gelukkig ben ik dat jullie hier op 10 
juni bij kunnen zijn! Ik wil jullie bedanken voor de steun en interesse die jullie altijd getoond 
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